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ABSTRACT 
 
Influenza is a contagious respiratory disease often disregarded due to the mild symptoms 
associated with it. The economic burden that flu cases impose on health care systems is 
substantial, not only due to influenza pandemics, but also to required hospitalizations and 
the need for yearly revisions of seasonal influenza vaccines. The need for a universal 
influenza vaccine was already recognized by the Global Vaccine Action Plan. 
Currently, injection-based vaccination is the most common method for influenza 
immunization. However, evidence has shown that mucosal immune responses, 
representing an important first line of defense at these sites, since most pathogens enter 
the body through mucosal tissues, are most efficiently induced by administration of 
vaccines onto mucosal surfaces than injected vaccines. From the different mucosal 
tissues, the gastrointestinal tract is an attractive route to be explored for vaccination; 
nonetheless, oral influenza vaccines are not available yet. 
The intestinal homeostasis is tightly controlled by several components of the intestinal 
barrier, such as the mucus layer, epithelial cells with different functions and an underlying 
immune system that surveys the gut. Between microorganisms that normally inhabit our 
gut, food antigens constantly present in our diet and potential pathogens, the intestinal 
barrier has the difficult task of integrating external and internal signals received by 
different cells in order to establish the correct response, immunity or tolerance, according 
to the antigen. Hence, oral vaccines will encounter these same intestinal barrier 
components and face the same obstacles as any other oral antigen or gut microorganism. 
The UniVacFlu consortium is currently working to develop a new mucosal universal 
vaccine against influenza, exploring different immunogens, immunization routes and 
delivery systems. This study was undertaken to understand the potential of the influenza 
vaccine candidate CTA1-3M2e-DD and polysaccharidic lipidated nanoparticles (NPL) 
when immunization occurs through the oral route.  
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We found that, while CTA1-3M2e-DD revealed a poor ability to cross the intestinal 
epithelium and target intestinal antigen-presenting cells, NPL were found to readily 
overcome the intestinal barrier and were found associated with both CX3CR1+ 
macrophages and CD103+ dendritic cells. Two different routes of NPL uptake were 
identified: one depends on Goblet cell-associated passages that allow the transfer of high 
amounts of NPL from the lumen to the intestinal lamina propria; the second relies on the 
direct acquisition of NPL by CX3CR1+ macrophages in Peyer’s patches by extension of 
trans-epithelial dendrites. Moreover, NPL as an oral vaccine vector was able to deliver the 
loaded antigen in the intestinal lamina propria and enhanced antigen presentation to CD4+ 
T lymphocytes in different organs. Despite increasing the availability of antigen, NPL did 
not induce tolerance towards the formulated antigen and a Th1 immune response was 
found at the level of the Peyer’s patches. We also identified the contribution of the 
starvation period in the immune response induced by the NPL formulation in our model of 
oral immunization. The full potential of NPL as a vaccine vector is currently being further 
investigated to understand its immunomodulatory properties.      
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
1 INTRODUCTION 
 
1.1 Intestinal homeostasis 
The gastrointestinal (GI) tract is continuously challenged by a variety of environmental 
agents and has developed different mechanisms to maintain tissue homeostasis. Here, 
food antigens and microbes are introduced every day. In fact, 1014 bacteria are present in 
the human intestine, represented by approximately 1000 different species [1]. The 
intestinal microbiota has developed a symbiotic relationship with the host, benefitting from 
nutrients provided by the host and providing the host with degradation products and other 
dietary factors [2]. At the same time, the intestine also has to deal with pathogens and 
harmful agents introduced via the oral route. Such high antigen load represents a potent 
activation stimulus that the immune system has to tolerate or react against. To interact 
with all these agents, the organism has developed a complex barrier that protects from 
pathogens and simultaneously promotes tolerance towards the commensal microflora [2]. 
The different chemical and physical components of the intestinal barrier that allow such 
adaptability will be further detailed in the next sections. 
 
1.1.1 The intestinal barrier 
1.1.1.1 Mucus layer 
The mucus layer is the first barrier separating the host from the external world at mucosal 
surfaces. Throughout the GI tract, the characteristics of the mucus layer fluctuate 
according to the physiology and environment of each region. For instance, the mucus 
layer lining the stomach is extremely thick, as it should protect the epithelium against the 
acidic pH; in the intestine, this layer is thinner, allowing the absorption of digested 
nutrients [3]. Variations in mucus properties also occur in the different intestinal segments. 
The small intestine presents a discontinuous and uneven mucus layer, whereas the colon, 
where the bacterial load is higher, is covered by a thicker mucus layer [3]. Here, a 
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compact inner layer is firmly attached to the epithelium and is sterile, while an outer and 
lose layer provides a colonization niche for the intestinal flora, by offering nutrients and 
preventing their clearance [4]. 
The mucus is formed by mucins, high molecular weight proteins produced and secreted 
by specialized epithelial cells, called Goblet cells. Mucus composition also includes other 
proteins, carbohydrates, salts, lipids, cellular debris, but mucin (MUC) 2 has been 
identified as the main component of intestinal mucus, both the inner and outer layers [4]. 
Being extensively glycosylated, MUC2 and other mucins confer gel-like properties to the 
mucus that protect against bacterial invasion and allow the concentration of various 
molecules (e.g. antimicrobial peptides and secretory immunoglobulin (Ig) A) close to the 
epithelium, helping to maintain sterility at this level [3,5].     
As the first barrier encountered by microbes, the intestinal mucus layer has the dual 
function of providing a niche for the commensal microflora, while preventing tissue 
invasion by not only the later but also pathogens. The role of the mucus layer in 
maintaining intestinal homeostasis has been shown in MUC-deficient mouse models. 
Indeed, Muc2-/- mice develop spontaneous colitis at an early age [6] and are more 
susceptible to infectious colitis triggered by Citrobacter rodentium [7] and Salmonella 
enterica serovar Typhimurium [8]. Velcich and colleagues also demonstrated the 
contribution of MUC2 in colorectal cancer suppression [9]. Other than a barrier between 
the host and the intestinal flora, mucus can also exert an immunomodulatory function on 
intestinal antigen-presenting cells (APCs). In fact, MUC2 is able to bind dendritic cells 
(DCs) through galectin-3, Dectin-1 and FcγRIIB, impairing the expression of inflammatory 
signals via β-catenin activation and simultaneously increasing the production of 
tolerogenic signals leading to differentiation of regulatory T cells (Tregs) in response to 
lipopolysaccharides (LPS) stimulation [10]. 
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1.1.1.2 Antimicrobial peptides 
Antimicrobial peptides are small molecules able to restrain the bacterial burden in the 
intestine, as well as prevent an excessive contact between the epithelium and bacteria 
[2,11]. This group of molecules includes defensins, C-type lectins, cathelicidins, and 
lipocalins, which are mainly produced and secreted into the intestinal lumen by Paneth 
cells located at the base of intestinal crypts [11–13]. These peptides exert their function 
through different mechanisms, which confers flexibility in targeting different groups of 
bacteria. Defensins are often found to attach to the outer membrane of Gram-negative 
bacteria, forming a “pore-like” structure through enzymatic digestion, whereas lipocalins 
obstruct the acquisition of essential metals required for bacterial growth [11,14]. 
Production of antimicrobial peptides can occur in a constitutive manner, but can be also 
triggered by bacterial sensing. For example, germ-free mice are able to produce the same 
mature intestinal defensins as mice colonized by a normal microflora [15]. Nevertheless, 
production of other antimicrobial peptides has been shown to depend on recognition of 
bacterial factors through Toll-like receptors (TLRs) [13] or Nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2) [16] on Paneth cells. Moreover, 
taking advantage of small intestine organoids, Farin and colleagues demonstrated that 
degranulation of Paneth cells is not entirely dependent on activation of Pattern 
Recognition Receptors (PRRs), but that interferon (IFN)γ produced by bacterial activated 
natural killer (NK) T and CD3+ T cells is the trigger for lysozyme and defensin secretion 
[17]. 
Since many antimicrobial peptides share similar functions, their importance in maintaining 
intestinal homeostasis has been addressed using a variety of transgenic mouse models. 
In fact, mice depleted of Paneth cells or Myd88-/- mice (that present a decreased 
expression of intestinal antimicrobial peptides) show higher translocation of both 
commensal bacteria and pathogens, such as S. Typhimurium. Systemic spreading of this 
pathogen is also observed in these models [13]. Mice lacking the matrix 
metalloproteinase-7 encoding-gene (required for α-defensin proteolytic activation) also 
exhibit higher susceptibility to infection [18] and alterations in microbiota composition, but 
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not in total bacterial numbers [19]. Alterations in microbiota were found as well in 
transgenic mice expressing human defensin-5 [19], which seem to be more protected 
against S. Typhimurium infection [20].  
 
1.1.1.3 Secretory IgA 
The secretion of IgA, the most abundant Ig in mucosal secretions, acts as another line of 
defense in the intestine, controlling the translocation of bacteria across the epithelial 
barrier.  
Induction of IgA-producing B cells occurs in different compartments of the gut-associated 
lymphoid tissue (GALT), namely Peyer’s patches (PP), isolated lymphoid follicles (ILF) 
and lamina propria through various mechanisms [21]. IgA specific for the intestinal 
microbiota are produced upon stimulation of B cells by DCs that have sampled luminal 
bacteria in the PP [22] or directly from the gut lumen [23]. Also epithelial cells can induce 
class-switch recombination (CSR) by producing B cell activating factor (BAFF) belonging 
to the tumor necrosis factor (TNF) family and the proliferation-inducing ligand (APRIL) 
after TLR stimulation that are then recognized by their receptor on B cells [24]. 
T cell-independent IgA production by B cells was demonstrated by Macpherson and 
colleagues when DCs in the dome of PP sample the commensal flora and convey live 
bacteria to the draining mesenteric lymph nodes (mLN) [22]. This process allows the 
containment of the bacteria to the mLN, preventing bacterial dissemination through the 
lymphatic and blood systems. Induced IgA+ B cells can then recirculate through the 
mucosal tissues and home back to the gut as the result of their expression of gut homing-
receptors [25]. Reaching the intestine, the IgA dimers are transported through the 
epithelium into the intestinal lumen via the polymeric Ig receptor present at the basolateral 
membrane of the epithelial cells. The “secretory” IgA is then released in the lumen by 
proteolysis of the extracellular domain of the polymeric Ig receptor [24]. 
The role of IgA in controlling intestinal microbiota has been investigated through a variety 
of approaches. Peterson and colleagues found that germ-free immunodeficient Rag1-/- 
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mice administered with Bacteroides thetaiotaomicron show a more robust innate immune 
response compared to wild-type mice and to Rag1-/- mice implanted with B. 
thetaiotaomicron specific IgA-producing hybridoma cells, suggesting the role of IgA in 
reducing intestinal pro-inflammatory signaling [26].  Moreover, mice deficient for Aicda and 
IgA present an expansion of anaerobic bacteria, including segmented filamentous 
bacteria, resulting in systemic hyperactivation of germinal center B cells [27,28]. 
 
1.1.1.4 Epithelium 
The intestinal epithelium is a permeable barrier involved in the prevention of uncontrolled 
translocation of food antigens and bacteria, regulation of fluid absorption and secretion of 
various molecules. It is composed of a layer of columnar epithelial cells with intercellular 
tight junctions and adherens junctions located near the apical surface of the intestinal 
epithelial cells, that prevent paracellular traffic of certain molecules, whereas the brush 
border on the apical side avoids microbial attachment and invasion [11]. Different 
specialized cells are present in the epithelium and are involved in the maintenance of 
intestinal homeostasis. For instance, microfold cells (M cells), located in the follicle-
associated epithelium (FAE) that line PP, colonic patches and ILF, are characterized by 
irregular microvilli on the apical membrane, and by a pocket-like microfold structure on the 
basal side in contact with T and B lymphocytes, macrophages and DCs [29]. The structure 
of these cells is consistent with their function to transport antigens. Other cells, include 
Goblet cells, important for the formation of the mucus layer, and Paneth cells, that 
produce antimicrobial peptides and have secretory functions.  
The epithelium was considered for a long time just a mechanical barrier impeding the 
uncontrolled translocation of invading pathogens. But this limited view has been changed 
by the observation that the epithelium also takes an active part in immunological 
processes [30]. Indeed, these cells may recognize conserved pathogen-associated 
molecular patterns (PAMPs), which are shared by pathogenic and non-pathogenic 
bacteria, through expression of PRRs, sending signals to the underlying mucosa. PRRs 
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are classified in four main groups, namely TLRs, nucleotide-binding domain and leucine-
rich repeat containing receptors (NLRs), retinoic acid-inducible gene-I-like receptors 
(RLRs) [31] and C-type lectin receptors (CLRs) [32]. The key mechanism to discriminate 
invasive pathogens, which can cross the epithelial monolayer, from the commensal 
microbiota, and to prevent responses to the bacterial components in the gut lumen, 
preserving the ability to mount responses against pathogens, is the compartmentalization 
of PRRs to the basolateral membrane or into the cytosol [30,33–35]. Indeed, in vitro 
studies have shown that when TLR9 is stimulated from the apical side, there is a defective 
activation of the nuclear factor kappa B (NF-κB) pathway and a different gene expression 
profile was found between cells stimulated apically and basolaterally [36]. Also, mouse 
models deficient for different TLRs were reported to spontaneously develop colon 
inflammation or increased susceptibility to experimental colitis [34,36–39].  
Intestinal epithelial cells are also involved in conditioning the intestinal hypo-
responsiveness of underlying APCs to harmless stimuli through the secretion of cytokines 
[30]. Such conditioning renders DCs “tolerogenic”, that in turn induce tolerogenic T cell 
responses [40–42]. The opposite happens too, as in the presence of inflammatory signals, 
the intestinal epithelium releases inflammatory cytokines and chemokines that recruit non-
educated DCs, initiating an inflammatory responses [30]. A variety of immune conditioning 
factors were found to be produced by epithelial cells, including transforming growth factor-
β (TGF-β), retinoic acid (RA), prostaglandin E2 and thymic stromal lymphopoietin (TSLP), 
that have been shown to play a major role in the induction of tolerance [30]. 
 
1.1.1.5 Immune cells 
The intestinal immune system, generally called GALT consists of lymphocytes scattered in 
the intestinal epithelium and lamina propria, as well as organized tissues, like PP, mLN 
and ILF, responsible for the induction of immune responses. PP and ILF can be found in 
the small intestine, whereas patches similar to ILF are found in the colon [43]. 
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Between the different cell types that constitute the intestinal immune barrier, APCs play an 
important role in maintaining immune homeostasis. This group of cells is composed of a 
large number of mononuclear cells, including macrophages and DCs, and over recent 
years there was a growing interest in characterizing these different subpopulations of 
phagocytes and their role in regulating mucosal innate and adaptive immune responses, 
in both the steady-state and inflammatory conditions. In the small intestine lamina propria, 
two main populations of developmentally and functionally non-overlapping phagocytes 
have been described and can be distinguished by their expression of CX3CR1 and CD103 
[44,45] (Fig. 1.1). These two populations will be further described in the next sections. 
 
 
Figure 1.1. Origin, phenotype and function of the main subsets of intestinal APCs. 
The common macrophage-dendritic cell precursor (MDP) gives rise to classic DC precursors and 
monocytes in the bone marrow. From these, classic DC precursors differentiate into CD103+ 
lamina propria DCs, that can give rise to a CD11b- and a CD11b+ populations, and Ly6C+ 
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monocytes differentiate into CX3C chemokine receptor 1 (CX3CR1)+ lamina propria mononuclear 
phagocytes. Adapted from Varol et al., Nature Reviews Immunology, 2010 [46]. 
 
1.1.1.5.1 CX3CR1+ macrophages 
CX3CR1, also known as Fractalkine receptor, is mainly involved in leukocyte adhesion 
and migration and its main ligand CX3CL1 is mostly expressed by epithelial and 
endothelial cells in the intestine [47,48]. The expression of this receptor has been 
associated with a subset of lamina propria phagocytes able to form trans-epithelial 
projections and capture luminal bacteria, such as Salmonella enterica [23,49–51]. This 
characteristic depends on the expression of the Fractalkine receptor and requires the 
involvement of epithelial cells forming tight junction-like structures, as demonstrated in 
experiments with bone marrow chimeras [50].  
Initially, and due to the lack of specific markers to unequivocally classify DCs and 
macrophages in non-lymphoid tissues, these cells were thought to be DCs. However, a 
detailed characterization of these cells, both at the phenotypical and functional level, 
revealed that they share common features with macrophages [52]. The CX3CR1+ lamina 
propria population derives from Ly6Chigh blood monocytes and is dependent on 
macrophage-colony stimulating factor (M-CSF) for its development [45,53]. This 
population can be defined by expression of specific phenotypical markers (F4/80+ MHC-II+ 
CD11c+ CX3CR1+ CD103- CD11b+) [52,54,55]. CX3CR1+ cells are highly phagocytic [56], 
cannot migrate from the lamina propria to the mLN (due to lack of CCR7 upregulation) 
[44] and have poor ability in priming naïve T cells, though they were already reported to 
induce a helper T (Th) 1/Th17 cell differentiation [56]. Different levels of CX3CR1 
expression, however, are associated with different functional subsets in this population, as 
CX3CR1int cells were found to migrate, efficiently prime T cells and respond to Flt3 ligand, 
similarly to DCs [57]. Additionally, antibiotic-induced dysbiosis was shown to trigger 
CX3CR1high macrophages to migrate into the mLN in a CCR7-dependent manner [58]. 
20 
 
Extension of dendrites and luminal sampling by this population have been shown to be 
induced by TLR ligands and bacteria, such as Salmonella [50], depending on the MyD88 
signaling pathway [59]. These cells can also acquire antigens from the blood stream that 
are then cross-presented to CD8+ T cells, which in turn express interleukin (IL)-10, IL-13 
and IL-9 and migrate to the intraepithelial compartment [60]. 
CX3CR1+ cells have been shown to play an important role in the establishment of oral 
tolerance. Indeed, F4/80+ CX3CR1high macrophages produce high levels of IL-10 and 
acquire an anti-inflammatory phenotype when stimulated with LPS [54,61]. Moreover, 
mice lacking CX3CR1 showed impaired local Treg expansion and failed to establish oral 
tolerance due to a reduced capacity of IL-10 production by CX3CR1-expressing 
macrophages [62].  
Inflammatory conditions, on the other hand, lead to the differentiation of E-cadherin+ 
F4/80int CX3CR1int CD11b+ macrophages from Ly6Chigh monocytes that are then able to 
produce pro-inflammatory cytokines, such as IL-12, IL-23 and TNF-α [54,63]. CCR2- and 
CX3CR1-deficient mice (lacking two receptors needed for Ly6Chigh monocyte recruitment 
to the inflamed tissue) are also less susceptible to colitis after dextran sodium sulfate 
(DSS) treatment [64,65]. 
 
1.1.1.5.2 CD103+ dendritic cells 
CD103 (also called integrin αE) is expressed by a subset of bona fide lamina propria DCs. 
These cells derive from pre-DCs and expand in response to Flt3 ligand and granulocyte-
macrophage colony stimulating factor (GM-CSF) [44,45,53,66]. The best known ligand for 
CD103, E-cadherin, is mainly expressed by epithelial cells [67], which suggests its 
involvement in the maintenance of these cells (as well as CD103+ CD8+ T cells) in the 
intestinal tissue. They also express CCR7, allowing them to migrate to the mLN 
[44,53,68]. Migration can occur under steady state conditions, but TLR stimulation can 
further increase the traffic of these cells to mLN, as supported by studies showing that 
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after oral infection with S. Typhimurium, CD11b+ CD103+ DCs are the only DC subset in 
the draining mLN containing green fluorescent protein (GFP)-labeled Salmonella [53]. 
In the mLN, under steady state conditions, CD103+ DCs induce the differentiation of naïve 
CD4+ T cells into forkhead box P3 (Foxp3)+ Tregs, through a mechanism dependent on 
RA and TGF-β [69,70], indicating their contribution in the maintenance of tolerance. They 
also induce the expression of gut homing molecules, such as CCR9 and α4β7, on T 
lymphocytes [68,71,72]. This ability, as well as other tolerogenic properties of CD103+ 
DCs, are conditioned by vitamin A that is introduced through the diet [73]. Additionally, the 
expression of IDO, an enzyme involved in tryptophan catabolism, is also required for their 
induction of Tregs [74]. The inhibition of this enzyme results in a failure in the 
establishment of tolerance to fed antigens and increased susceptibility in colitis models. 
As conventional DCs, intestinal lamina propria CD103+ DCs express CD11c and MHC-II 
and can be further subdivided into different populations by their expression of CD8α and 
CD11b [75]. CD8αhigh CD11b- cells are mainly found in PP and ILF [53]. However, this 
population still persists in Rorγt-deficient mice, which lack PP and ILF, suggesting that 
they are not exclusively found in these intestinal compartments [57]. Transcription factors, 
such as Id2 and IRF8, are critical for the development of CD8αhigh CD11b- cells [53,76] 
and, similarly to CD8α+ conventional DCs, these cells are highly efficient in cross-
presentation of cell-associated antigens [54]. CD8α- CD11bhigh cells express TLR5 and 9 
and, in response to flagellin, this subset induces a T cell-independent differentiation of 
naïve B cells to IgA+ B cells and polarization of T cells to a Th1/Th17 phenotype [75,77].  
Under inflammatory conditions, the tolerogenic features of the CD103+ DCs are lost and 
they acquire a pro-inflammatory phenotype. Laffont and colleagues have shown that in a 
model of T cell-induced colitis, the ability to induce Foxp3+ Tregs is compromised in 
CD103+ DCs sorted from mLN and a Th1 phenotype is instead imprinted [78]. 
Furthermore, CD11b+ CD103+ DCs act as a first line of defense to bacterial infection, as 
upon flagellin stimulation, this population from the small intestine rapidly increases its 
22 
 
expression of IL-23 subunits IL-23p19 and IL-12p40 and mediates IL-22-dependent 
antimicrobial peptide secretion by epithelial cells [79]. 
 
1.1.2 Antigen uptake in the intestine 
The different components of the intestinal barrier participate in a complex network of 
interactions in order to avoid the entry of harmful organisms and other environmental 
agents in the intestinal tissue, as described in the previous sections. Nevertheless, the 
intestinal immune system needs to respond adequately to the different stimuli present in 
the intestinal lumen. Harmless agents, as commensal bacteria and food antigens, have to 
be distinguished from detrimental ones, including pathogens, in order to mount tolerogenic 
or protective immune responses, accordingly. Sampling of intestinal antigens by APCs is 
the initiating step of such regulated immune responses that ensure a balanced intestinal 
homeostasis. 
 
 
Figure 1.2. Routes of antigen uptake in the intestine.  
Studies have identified different pathways for antigen uptake, including: (1) transcytosis by M cells 
in FAE; (2) extension of trans-epithelial dendrites by CX3CR1+ APCs; (3) extension of dendrites 
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through M cell transcellular pores by LysoDCs in PP; (4) transfer of small molecules by Goblet 
cells; and (5) transfer of antigen-containing endosomes by enterocytes. Adapted from Mabbott et 
al., Mucosal Immunology, 2013 [80]. 
 
In the past few years, several mechanisms for transport of luminal antigens across the 
intestinal epithelium have been described, involving both epithelial cells and immune cells 
(Fig. 1.2). 
M cells, abundantly present in the FAE, covering PP and ILF, are specialized transcytotic 
epithelial cells that greatly contribute to antigen transport into these inductive immune 
compartments. M cells are able to actively internalize particulate material through a 
number of mechanisms (macropinocytosis, endocytosis in clathrin-coated vesicles, actin-
dependent phagocytosis), releasing it in basolateral “intraepithelial pockets”, where APCs 
can take up the shuttled material [80,81]. The transcytotic function of M cells can be 
further enhanced by microbial products, increasing antigen uptake through the FAE [82]. 
In fact, several pathogens take advantage of this feature of M cells to breach the intestinal 
barrier. This process occurs due to the interaction between microorganisms and 
molecules that are specifically expressed on the apical surface of M cells. For instance, 
glycoprotein 2 (GP2) is highly expressed by M cells [83] and selectively binds to FimH, a 
component of the type I pili found on the membrane of bacteria, such as S. Typhimurium. 
The contribution of GP2 in M cell-mediated uptake was confirmed by a defective 
transcytosis of FimH+ bacteria, decreased bacterial load and antigen-specific immune 
responses in PP when GP2 was absent in the host [84]. Another receptor on M cells that 
is likely to contribute to the uptake of microorganisms by these specialized cells is the 
cellular prion protein (PrPC) [85]. Nakato and colleagues have shown that Brucella abortus 
can interact with PrPC on M cells and trigger its internalization by expressing heat shock 
protein 60 on the cell surface [86]. Moreover, expression of the complement C5a receptor 
on M cells allows the binding and uptake of Yersinia enterocolitica after oral infection, as 
this bacterium expresses an homologous protein to the Skp α1 domain of Escherichia coli, 
a ligand of C5a receptor [87]. Alternatively, an indirect uptake can also occur through M 
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cells, as they rely on secretory IgA to bridge the transport of intestinal antigens. This 
feature of M cells depends on their expression of an IgA-specific receptor, different from 
FcαRI [88], that binds to secretory IgA-antigen immune complexes of various sizes and 
enables their transference into PP [89]. 
Compared to M cells, other epithelial cells have a poor endocytic and transcytotic 
capacity. Still, high resolution imaging techniques revealed that FAE enterocytes are able 
to transport prions within large endosomes and exocytose their cargo into the extracellular 
space of the sub-epithelial dome (SED) [90]. Moreover, Ig-bound antigens can also be 
transported from the lumen to the lamina propria by villous epithelial cells expressing the 
neonatal Fc receptor, which is involved in both IgG secretion into the lumen and sampling 
of IgG-antigen complexes [91]. Epithelial cells with secretory functions, as is the case of 
Goblet cells, were also implicated in the trafficking of intestinal antigens. McDole and 
colleagues have demonstrated that different low molecular weight soluble antigens can 
enter the lamina propria through Goblet cell-associated passages and be directly 
delivered to CD103+ DCs [92]. In addition, the paracellular diffusion of antigens across the 
intestinal epithelium can be included in the mechanisms of antigen uptake, as small 
molecules may pass between adjacent epithelial cells due to the existence of pores in the 
tight junctions [93]. 
On the other hand, routes of antigen sampling that are not mediated by epithelial cells and 
rely on the direct uptake by intestinal APCs have also been described. In PP, Lelouard 
and colleagues have found that CD11c+ CX3CR1+ cells expressing lysozyme M, named 
LysoDCs, capture inert particles and S. Typhimurium by extending dendrites through M 
cell specific transcellular pores. This process is accompanied by recruitment of M cell 
junctional adhesion molecule A and epithelial cell adhesion molecule [94]. In the villous 
lamina propria, CD11c+ APCs were also found to directly sample luminal antigens. 
However, differently from the previous case, extension of dendrites by these cells does 
not involve transcellular pores. Instead, their dendrites cross the epithelial barrier in a 
paracellular way without disruption of its integrity and relies on the formation of tight 
junctions between epithelial cells and APC’s protrusions [23]. Furthermore, these trans-
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epithelial extensions were identified mainly in the proximal jejunum, presenting a  
"balloon" shape, and their discreet presence in the terminal ileum was markedly increased 
after infection with different Salmonella strains [50]. Another study further characterized 
these cells as CX3CR1+ APCs, showing the involvement of CX3CR1 in the formation of 
trans-epithelial dendrites through experiments with mice lacking this chemokine receptor 
[49].  
 
1.1.3 Oral tolerance 
Immune tolerance is considered a state of unresponsiveness of the immune system 
towards a particular antigen that has the potential to trigger an immune response. As 
described in the previous sections, the intestinal mucosa is permanently in contact with 
many different antigens, including harmless food antigens and commensal 
microorganisms. Hence, in order to maintain tissue homeostasis and prevent exacerbated 
immune responses against such antigens, the intestinal immune system developed 
mechanisms that allow the induction of tolerance, both in the intestine and systemically, 
upon encounter with these antigens, known as oral tolerance [93]. 
Oral tolerance is mainly induced in the draining mLN. Different studies have shown that in 
mice devoid of mLN [95] or subjected to mesenteric lymphadenectomy [96], induction of 
oral tolerance to food antigens fails. Additionally, PP may also function as an induction 
site for oral tolerance, since mice treated with lymphotoxin β-receptor Ig fusion protein in 
utero (lacking PP) are not able to mount oral tolerance to ovalbumin (OVA) [97]. 
Nevertheless, the contribution of PP to oral tolerance establishment is still controversial, 
as other studies have pointed in the opposite direction. Indeed, Enders and colleagues 
have shown that rats subjected to surgical removal of PP present a similar response to 
control animals [98]. Despite strong evidence supporting the role of the GALT in the 
induction of oral tolerance, some studies have revealed that this immune response can 
also be attained through other tissues. By intraperitoneal injection of serum from tolerized 
mice (expected to contain processed antigen), Kagnoff was able to demonstrate the 
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induction of tolerance in recipient animals [99]. In addition, antigen delivery directly in the 
hepatic portal vein can have similar effects to oral delivery [100]. These observations 
suggest that the establishment of oral tolerance relies on the transport of antigens to the 
GALT, as well as on their systemic dissemination and transport to the liver through portal 
circulation [101]. 
Besides the induction site, the establishment of oral tolerance relies on a complex 
interaction of different factors. The dose and frequency of antigen administration can 
dictate tolerance induction, as high doses of antigen can lead to anergy and deletion of 
antigen-reactive T cells [102,103], whereas repeated low doses of antigen might induce 
Tregs [104]. The differentiation of Tregs is indeed an essential step in mounting tolerance 
to orally delivered antigens. This process depends on antigen uptake by intestinal APCs, 
particularly DCs endowed with migratory capacity, that then transport the processed 
antigen to the draining mLN. Here, DCs present their cargo to T cells and induce their 
differentiation towards a regulatory phenotype, as well as expression of gut-homing 
receptors that allow Treg migration to the intestine where their regulatory function can be 
exerted. The induction of tolerogenic characteristics on T cells is shaped by different 
aspects, including the local environment from where APCs migrate and the innate 
features of the various APC subsets presenting the antigen (as described in sections 
1.1.1.5.1 and 1.1.1.5.2).   
Tregs control and suppress effector immune responses against specific antigens. These 
cells encompass different subsets of both CD4+ and CD8+ T cells, but two main subsets 
are usually recognized according to their origin: naturally occurring CD4+ CD25+ Tregs 
and inducible Tregs. The first originate in the thymus and suppress self-reactive T cells in 
the periphery; the second differentiate in peripheral tissues upon antigen presentation by 
APCs in the absence of co-stimulatory signals and/or in the presence of tolerogenic cues. 
Among the different inducible Tregs, Tregs expressing the transcription factor Foxp3 have 
been linked to the occurrence of oral tolerance [62]. Adoptive transfer of naïve OVA-
specific T cells into congenic recipients has confirmed the conversion of OVA-specific 
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CD4+ Foxp3+ T cells in the intestinal lamina propria and mLN after oral administration of 
this antigen [70]. CD4+ Foxp3+ T cells can be induced by specific subsets of DCs in the 
presence of RA and TGF-β [69,70]. IL-2 was also shown to be required for the 
differentiation of Foxp3+ Tregs [105]. Furthermore, the expression of gut-homing 
receptors, such as α4β7, and the correct environment for Foxp3+ Tregs expansion are 
fundamental for their function in oral tolerance. Indeed, Hadis and colleagues have shown 
that oral tolerance is compromised in β7-deficient mice [62] and, along with other studies, 
have demonstrated the role of IL-10 produced by lamina propria APCs in the induction of 
Tregs and in the maintenance of Foxp3 expression [61,62,106]. 
 
1.2 Vaccination 
The introduction of vaccination is regarded as the most effective intervention for protection 
against infectious diseases and has contributed significantly to an increase in life 
expectancy [107]. Mass vaccination programs have spared millions from the morbidity and 
mortality associated with such diseases and resulted in the total eradication of smallpox 
[108]. However, for some infectious diseases, further improvement is still required in 
vaccine research and development to provide complete protection against them. 
Numerous pathogenic bacteria and viruses colonize and invade the host at mucosal 
surfaces, being instrumental the generation of a first line of defense at the site of infection, 
including induction of pathogen-specific secretory IgA [109,110]. 
 
1.2.1 Influenza vaccination 
Influenza is a contagious respiratory disease often disregarded due to the mild symptoms 
associated with it, including cough, sore throat and fatigue that go away in few days. 
However, susceptible human populations (young children, elderly adults, people with 
chronic medical conditions, pregnant women) are at high risk of developing serious flu 
complications, resulting sometimes in death. Circulating influenza viruses undergo 
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antigenic drift, i.e. small changes in their genetic material that happen gradually as the 
virus replicates [111]. Accumulation of these genetic changes over time leads to 
antigenically diverse viruses. Once this happens, the immune system might not be able to 
fight the virus anymore, as the antibodies generated upon previous encounters cannot 
recognize the “new” virus. For this reason, every year the composition of flu vaccines has 
to be reviewed and updated in order to keep up with the evolving viruses and adequately 
protect the population. Less frequently, human type A influenza viruses (or animal 
influenza viruses) can also undergo antigenic shift, a major change that results in new 
hemagglutinin or hemagglutinin and neuraminidase combinations [111]. In such cases, 
most people do not have immunity to the virus and, as happened in 2009 when a H1N1 
virus emerged, an influenza pandemic occurs, causing a considerable death toll.    
The economic burden that flu cases impose on health care systems is substantial, not 
only due to influenza pandemics, but also to required hospitalizations and the need for 
yearly revisions of seasonal influenza vaccines. Moreover, the global production and 
distribution capacity of both seasonal and pandemic influenza vaccines cannot keep up 
with demand, and developing countries are affected by vaccine shortage [112]. The need 
for a universal influenza vaccine – a vaccine eliciting long-lasting broader immune 
responses against a wider range of influenza viruses and that eradicates the necessity for 
annual updates of seasonal vaccines and production of new vaccines upon advent of 
influenza pandemics – was already recognized by the Global Vaccine Action Plan, that 
aims to generate one by 2020.  
 
1.2.1.1 CTA1-3M2e-DD: a universal influenza vaccine candidate 
In an attempt to abolish cholera toxin (CT) toxicity while maintaining its adjuvanticity, the 
fusion protein CTA1-DD was generated [113]. This fusion protein is composed of an 
enzymatically active CT A1 subunit (CTA1) genetically fused through its C-terminal end to 
a dimer of the D region (DD) of Staphylococcus aureus protein A, an Ig-binding domain. 
CTA1-DD was found to target B cells in vivo [113] and to bind to both Fc and Fab 
29 
 
fragments and to different Ig classes, preferentially to the various IgG subclasses 
[113,114]. Immunization with CTA1-DD generates a Th1/Th2 response, resulting in 
increased T cell proliferation, germinal center formation and antibody production as well 
as cytotoxic T lymphocyte activity [113,115–117]. Moreover, this fusion protein has been 
combined with different antigens and has been shown to confer protective responses in 
different disease models including chlamydia, rotavirus, influenza and Helicobacter pylori 
[118–122].  
Amongst the different approaches to generate a universal influenza vaccine, M2e-based 
vaccines have been extensively studied [123]. M2e (the extracellular domain of matrix 
protein 2) is highly conserved among all human influenza A viruses [124] and, as such, is 
highly attractive as a viral antigen. The interest in M2e for universal vaccines has been 
supported by studies showing that vaccines carrying this antigen elicit a high degree of 
protection upon virus challenge that correlates with production of anti-M2e antibodies 
[125–127].    
When M2e was incorporated as a three tandem repeat into the CTA1-DD adjuvant, the 
universal influenza vaccine candidate CTA1-3M2e-DD was able to protect against a lethal 
dose of live influenza virus upon intranasal immunization and promoted high M2e-specific 
serum IgG and mucosal IgA antibody titers [121]. Recently, it has also been shown that 
CTA1-3M2e-DD-induced protection after mucosal immunization relies not only on M2e 
specific antibodies, but also M2e-specific memory CD4+ T cells that are found in the 
lungs, rapidly expanded upon viral challenge infection and present a Th17 phenotype 
[128]. 
 
1.2.2 Mucosal vaccination vs parenteral vaccination 
The majority of pathogens enter the body through mucosal surfaces. Thus, mounting a 
first line of defense at these sites to protect from pathogen invasion and infection is 
fundamental. It is now generally accepted that mucosal vaccination, that includes oral, 
nasal, sublingual, and genital tract vaccination, is the most effective way to achieve 
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successful protective immune responses in mucosal tissues [109,110]. This is explained 
by the ability of mucosal vaccines to induce both humoral and cell-mediated immune 
protection at the level of mucosal surfaces, but also systemically [109,110]. Indeed, 
mucosal vaccines are taken up by APCs at the immunization site and are then presented 
to B and T cells in the draining lymph nodes, where they acquire tissue-specific homing 
receptors. This enables antigen-specific memory and effector immune cells to exit the 
draining lymph nodes, enter the blood circulation and settle in the mucosal tissue [110]. 
Moreover, mucosal vaccination can trigger antigen-specific IgA production not only at the 
tissue of immunization, but also in distal mucosal surfaces [109]. Mucosal surfaces are 
also densely equipped with APCs, as they are constantly in contact with the external world 
and vulnerable to invading pathogens, improving the uptake of vaccines at these sites. 
Nevertheless, most vaccines in use today are administered by parenteral injection. This 
vaccination route is not the most effective, as it generally fails to elicit a pathogen-specific 
mucosal immunity and, for many pathogens, optimal protection requires both mucosal and 
systemic immune effectors. This is due to the systemic homing specificity of effector 
lymphocytes activated in the peripheral lymph nodes. Moreover, subcutaneous tissue and 
muscle contain very low numbers of APCs [129]. 
The advantages of mucosal vaccines over parenteral vaccines are observed at many 
other levels. For instance, administration of mucosal vaccines is easier and does not 
require professionals with medical training or a clinical setting, as it eliminates the use of 
needles and syringes, and prevents concerns regarding their reuse and disposal that 
often leads to vaccination-related infections and environmental hazards. This also renders 
mucosal vaccines more suitable for mass vaccination and prevention of pandemic spread 
of infections [110]. Better compliance is achieved with mucosal vaccines, since parenteral 
vaccines often cause pain, local swelling and stiffness. Moreover, regulatory requirements 
for the production of mucosal vaccines are less stringent and consequently production is 
cheaper [130]. This is due to the fact that mucosal surfaces, such as the intestine, already 
present high numbers of bacteria, which eliminates the necessity to purify oral vaccines 
from bacterial by-products to the same level as vaccines injected parenterally [110].  
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Considering these advantages, few licensed mucosal vaccines are currently available in 
the market, including vaccines for poliovirus, S. Typhimurium, Vibrio cholerae and 
rotavirus [110]. Several studies involving oral vaccines have been delayed due to the 
challenges that this route imposes. In fact, as with any other orally delivered antigen or 
pathogen, oral vaccines face many obstacles in the GI tract. These include an extremely 
variable pH throughout the GI tract, dilution of the vaccine dose in mucosal secretions, 
entrapment in the mucus layer, exclusion by epithelial barriers, and enzymatic 
degradation by digestive proteases, just to mention a few [109]. To overcome some of 
these obstacles, high doses of vaccine are required; however, the dose that is actually 
taken up by the host through the intestinal mucosa cannot be precisely quantified. Another 
important hurdle that oral vaccines face is the induction of oral tolerance, which 
completely compromises the overall goal of vaccination. Indeed, if taken up, soluble non-
adherent antigens, as is the case of some oral vaccines, usually induce immune tolerance 
[131].    
 
1.2.3 Particulate vaccines for mucosal immunization 
In recent years, different delivery strategies have been studied in order to address the 
challenges described above. These include the development of particulate vaccines that 
protect the antigen and incorporate features shared by mucosal pathogens that are 
successful in invading the host. 
Indeed, different studies have demonstrated protection from degradation of protein, 
peptide and DNA vaccines after inclusion in microparticles, liposomes or proteasomes 
[132–134]. Such delivery systems have also proven to retain the vaccine antigens on 
mucosal surfaces, increasing their uptake across the epithelium [135,136]. Particulate 
delivery systems also have the advantage of being easily transcytosed by M cells and this 
characteristic can be further enhanced by coupling ligands and antigens that target PP 
[136–138]. Importantly, particulate-based vaccine delivery systems not only have the 
potential to increase the uptake of their cargo, but can also act as vaccine adjuvants, as 
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some have been shown to efficiently modulate immune responses [139,140]. A summary 
of the different strategies to overcome the challenges that mucosal immunization imposes 
using particulate material is presented in Table 1.1. 
 
Table 1.1. Mucosal vaccination challenges and solutions from particle-based vaccine 
research.  
Adapted from Sahdev et al., Pharmaceutical Research, 2014 [141].  
 Challenges Solutions References 
Site of 
administration 
Induction of mucosal 
immunity via oral and 
intranasal administration 
Nanoparticles coated with or 
composed of mucoadhesive 
biopolymers 
Use of pH-responsive particles for 
protection of antigens from stomach 
acids and subsequent release in lower 
digestive tract 
[142–144] 
 
 
[145,146] 
Antigen delivery 
to lymph nodes 
Instability of particles in 
vivo 
Ineffective lymphatic 
transport of particles 
Increasing stability of lipid vesicles via 
interbilayer crosslinking 
Design of small (< 100 nm) and 
PEGylated nanoparticles for enhanced 
lymphatic drainage 
Direct intranodal injection of particle 
vaccines 
[147–150] 
 
[151–156] 
 
 
[157] 
Activation of 
APCs 
Promotion of APC 
activation and maturation 
to avoid immune 
tolerance 
Co-delivery of antigens and danger 
signals within particles 
Use of intrinsically immunostimulatory 
material as building blocks 
[146,158,159] 
 
[153,154,160,161] 
Intracellular 
antigen release 
Antigens trapped in 
lysosomes are degraded 
Cell-penetrating peptides for cytosolic 
antigen delivery 
pH-responsive polymers for endosome 
escape 
Reduction-sensitive conjugation of 
antigens to particles 
[162–164] 
 
[165–170] 
 
[153–156,167–
169,171] 
Vaccine 
preparation 
Loss of antigenicity and 
immunogenicity during 
particle synthesis 
Antigen loading into polymeric 
particles in aqueous conditions via 
self-healing process 
Use of cell membrane-decorated 
particles for adsorption and 
inactivation of bacterial toxin 
[172,173] 
 
 
[174] 
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2 AIM OF THE STUDY 
 
Although mucosal vaccines can elicit a more complete protective immune response, 
injected vaccines are still the most common ones. The oral route, particularly, offers many 
advantages in vaccination, but simultaneously many challenges, as the environment 
throughout the GI tract presents different threats to the stability of vaccines. Taking this in 
consideration and in the framework of the UniVacFlu project, whose overall goal is to 
develop a new universal influenza vaccine that is administered on a mucosal surface, the 
main aim of this project was to investigate the potential of an influenza vaccine candidate 
and nanoparticulate vaccine vectors generated in our consortium as an oral 
vaccine/delivery system. 
Thus, we proceeded through the following steps: 
 Characterization of the vaccine candidate/vaccine vector uptake in the small 
intestine; 
 Identification of the small intestine lamina propria APC subsets responsible for 
vaccine candidate/vaccine vector uptake, focusing on CX3CR1+ macrophages 
and CD103+ DCs; 
 Assessment of the effect of the vaccine vector on antigen delivery and antigen-
specific immune responses in a model of oral immunization; 
 Identification of conditions that might impact the outcome of immunization in 
this model; 
 Manipulation of the gastric pH for optimal function of the vaccine vector 
through the oral route. 
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3 MATERIALS AND METHODS 
 
3.1 Mice 
 
Six- to ten-week-old C57BL/6J and C57BL/6-Ly5.1 (B6.SJL-PtprcaPepcb/BoyCrl) mice 
were purchased from Charles River. Cx3cr1GFP/GFP (B6.129P-Cx3cr1tm1Litt/J) mice, 
expressing GFP under the control of the endogenous Cx3cr1 locus [175], and OT II 
(B6.Cg-Tg(TcraTcrb)425Cbn/J) mice, expressing the mouse α-chain and β-chain T cell 
receptor that pairs with the CD4 co-receptor and specifically recognizes chicken OVA323-
339 peptide in the context of I-Ab [176], were purchased from Jackson Laboratory. The 
heterozygous Cx3cr1GFP/+ mouse colony was obtained by Cx3cr1GFP/GFP males × 
C57BL/6J females mating. Mice were bred and maintained at the Animal Facility of the 
IFOM-IEO campus (Milan, Italy) under specific pathogen-free conditions. All experiments 
were performed in accordance with the Italian Laws (D.lgs. 26/2014), which enforce 
Directive 2010/63/EU (Directive 2010/63/EU of the European Parliament and of the 
Council of 22 September 2010 on the protection of animals used for scientific purposes). 
 
3.2 Fusion protein preparation 
 
The fusion protein CTA1-3M2e-DD (carrying three copies of the extracellular domain of 
the influenza virus M2 protein; amino acid sequence: SLLTEVETPIRNEWGSRSNDSSD) 
was produced by MIVAC Development AB (Gothenburg, Sweden), according to what was 
previously described [121,128], and provided by Prof. Nils Lycke’s laboratory (University 
of Gothenburg, Sweden). Briefly, the fusion protein was expressed in E. coli DH5 cells, 
which were grown in 500 mL cultures overnight in SYPPG medium with 100 µg/mL 
carbenicillin, at 37ºC. The fusion protein, produced as inclusion bodies, was washed 
before extraction by treatment with 8 M urea. After refolding of the protein by slow dilution 
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in Tris-HCl pH 7.4 at 4ºC, the fusion protein was purified by ion exchange and size 
exclusion chromatography, concentrated and submitted to sterile filtration. Protein 
analysis was performed with sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and protein concentration was determined using the DC Protein Assay (Bio-
Rad), according to the manufacturer’s instructions. The purified fusion protein was stored 
at -80ºC until use and it was routinely tested for the presence of endotoxin using the 
Limulus amebocyte lysate Endochrome assay (Charles River Endosafe). CTA1-3M2e-DD 
was conjugated with Alexa Fluor (AF) 488 or AF647 using the Antibody Labeling Kit 
(Thermo Fisher Scientific) and following the manufacturer’s instructions.  
 
3.3 Vaccine vector preparation 
 
 
Figure 3.1. Schematic representation of composition and preparation of NPL formulations. 
(A) NP+ are loaded with the anionic lipid DPPG to form NPL. (B) An antigen of interest (for 
example, OVA) is then loaded into NPL, obtaining an antigen:vaccine vector formulation. Adapted 
from Bernocchi et al., Journal of Controlled Release, 2016 [177]. 
 
Polysaccharidic lipidated nanoparticles (NPL) were produced (Fig. 3.1), characterized and 
conjugated as described previously [177,178] and provided by Prof. Didier Betbeder’s 
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laboratory (University of Lille, France). Briefly, maltodextrin (Roquette) was dissolved in 
water and a mixture of epichlorohydrin and glycidyltrimethylammonium chloride (Sigma-
Aldrich) in basic medium was added to the cationic polysaccharide, forming a gel. The gel 
was neutralized with acetic acid and crushed with a high pressure homogenizer, obtaining 
polysaccharidic cationic nanoparticles (NP+) that were then purified by tangential flow 
ultra-filtration to remove oligosaccharides, low-molecular weight reagents and salts, and 
freeze dried. Lyophilized NP+ were resuspended in a 70% (w/w) aqueous solution of the 
anionic lipid 1,2-dipalmitoyl-sn-glycero-3-phosphatidylglycerol (DPPG, Lipoid), which was 
incorporated by the nanoparticles, obtaining NPL. For OVA:NPL formulations, OVA 
(Sigma-Aldrich) was purified by gel filtration, the concentration of protein was evaluated 
using the Micro BCA Protein Assay Kit (Thermo Fisher Scientific), following the supplier's 
instructions, and 1 mg/mL of protein was loaded into sterile NPL (5 mg/mL) by mixing 
both, obtaining a 1:5 (w/w) OVA:NPL formulation. The characterization of the size (Z-
average), Zeta potential and polydispersity index of NPL and OVA:NPL formulations was 
performed with Zetasizer Nano ZS (Malvern Instruments) and is presented in Table 3.1. 
The analysis of the protein association to NPL was performed by native-PAGE, followed 
by silver nitrate staining to detect the unbound protein and measure the amount of 
associated protein. 
 
Table 3.1. Characterization of size, polydispersity index and Zeta-potential of empty NPL 
and OVA:NPL formulation used in this study.  
Adapted from Bernocchi et al., Journal of Controlled Release, 2016 [177]. 
 
 Z-average (nm) Polydispersity index Zeta-potential (mV) 
NPL 76.07 0.211 +44.2 ± 10.15 
OVA:NPL 1:5 w/w 62.39 0.236 +33.47 ± 8.417 
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When necessary, NPL and OVA were fluorescently labeled. For NPL detection, NP+ were 
covalently labeled with fluorescein isothiocyanate (FITC, Sigma-Aldrich). FITC was added 
to NP+ (NP+:FITC mass ratio of 10), solubilized in 0.1 M bicarbonate buffer pH 9.5, and 
the solution was mixed for 6h at room temperature and protected from light. NP+/FITC 
were then lipidated, as described above, to obtain NPL/FITC. Alternatively, the 
phospholipids of DPPG encapsulated in NP+ were labeled with 1.1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine perchlorate (DiD, Thermo Fisher Scientific). DiD (1 mg/mL 
in ethanol) was added to NPL at a final concentration of 0.7% (w/w of DPPG) and mixed 
for 30 min at room temperature in order to obtain NPL/DiD. Conjugation of OVA with 
tetramethylrhodamine-5-isothiocyanate (TRITC, Thermo Fisher Scientific) was performed 
following the same protocol used for NP+ labeling. After organic solvent evaporation, 
fluorescent NPL formulations were kept in the dark at 4ºC until use. 
 
3.4 Isolation of human peripheral blood mononuclear cells  
 
Human peripheral blood mononuclear cells (PBMCs) were isolated from heparinized 
blood from healthy donors. Approximately 40 mL of a buffy coat suspension were washed 
twice in phosphate-buffered saline (PBS) and the serum was discarded. The remaining 
volume of buffy coat was mixed with PBS up to a final volume of 35 mL by inverting the 
tube. The buffy coat suspension was gently layered on 15 mL of Ficoll (Biocol) and 
centrifuged at 1200 rpm for 30 min without brake. The PBMC ring was collected and 
washed three times with PBS. 
 
3.5 In vitro CTA1-3M2e-DD binding 
 
Mouse splenocytes were isolated from C57BL/6J mice as described in section 3.11. 
Human PBMCs were obtained as described in section 3.4. Increasing doses (0-2 µg) of 
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CTA1-3M2e-DD/AF488 were incubated for 1h at 4ºC with 106 mouse splenocytes or 
human PBMCs in 100 µL of 2% fetal bovine serum (FBS) in PBS. Cells were extensively 
washed in PBS to remove the unbound fusion protein and CTA1-3M2e-DD binding to B 
cells was detected by flow cytometry after staining mouse splenocytes and human 
PBMCs with anti-B220 (clone RA3-6B2, BD Pharmingen) and anti-CD19 (clone LT19, 
Miltenyi Biotech) antibodies, respectively. 
 
3.6 Ligated intestinal loop  
 
C57BL/6J and Cx3cr1GFP/+ mice were starved overnight (while allowing continuous access 
to water) in order to reduce the intestinal content and avoid competition of the injected 
agent with food antigens and feces. The next day, mice were anesthetized with 2.5% 
Avertin for the entire duration of the experiment. An incision was made on the skin to 
expose the peritoneum and another incision in the peritoneal wall allowed access to the 
intestine. A 3-4 cm segment of the small intestine was exposed, ligated at both extremities 
with surgical thread and fluorescently labeled CTA1-3M2e-DD (5-100 µg), NPL (50 µg), 
OVA:NPL (10 µg OVA:50 µg NPL) or PBS (vehicle) alone were injected into the loop in a 
volume of 100 µL. Mice were sutured, maintained in a recovery rack and sacrificed after 1 
or 2h for resection of the intestinal loops. Tissues were processed for confocal microscopy 
analysis.     
 
3.7 Intraduodenal administration 
 
C57BL/6J, Cx3cr1GFP/+ and C57BL/6-Ly5.1 mice were starved overnight. The next day, 
mice were anesthetized with 2.5% Avertin for the duration of the surgery. An incision was 
made on the skin and peritoneal wall, and CTA1-3M2e-DD or NPL formulations were 
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injected directly into the duodenum in a volume of 200 µL. Mice were sutured and 
maintained in a recovery rack until awake. 
 
3.8 Human intestinal specimens and ex vivo organ culture model 
 
Human intestinal (ileum) specimens were obtained from the healthy tissue of patients 
undergoing surgery for tumor resection. The tissue was placed in Hanks' Balanced Salt 
Solution medium supplemented with 100 IU/mL penicillin and 100 μg/mL streptomycin at 
4°C immediately after resection. To study whether NPL could be taken up in the human 
intestine, an ex vivo organ culture model allowing the maintenance of tissue polarization 
developed in our laboratory [179,180] (Fig. 3.2) was followed, with some modifications. 
Briefly, the intestinal explants were gently washed in Dulbecco's Modified Eagle Medium 
(DMEM), the mucosa was separated from the submucosa and the former was cut in 
approximately 1 cm2 pieces. With the apical side of the mucosa facing upwards, a plastic 
cloning cylinder (BellCo) was attached with surgical glue to the luminal surface of the 
explant. The explant was then placed on a metal grid positioned in a center-well organ 
culture dish (BD Falcon) filled with DMEM containing 15% FBS, 2 mM L-glutamine, 200 
ng/mL epidermal growth factor (Peprotech) and 10 µL/mL Insulin-Transferrin-Selenium-X 
(Gibco). To mimic physiological conditions, reconstitution of the mucus layer was allowed 
by placing the intestinal explant in a regular cell culture incubator without medium on the 
luminal side of the tissue. After 1h, 50 µL of supplemented medium alone or containing 20 
µg NPL/FITC was applied inside the cylinder, covering the luminal surface of the explant 
delimited by the cylinder, and incubation continued under the same conditions for an 
additional hour. The explants were then processed for confocal microscopy analysis after 
removal of the cylinder. 
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Figure 3.2. Ex vivo organ culture model.  
(A) Schematic representation of the technical setting viewed from the side and from the top. The 
intestinal explant is placed on a metal grid and a plastic cylinder is sealed on the luminal surface of 
the tissue. (B) Photograph of the assembled components of the organ culture model. (C) The 
stimulus is placed inside the cylinder, maintaining tissue polarization and mimicking physiological 
conditions, as the stimulus is only in contact with the luminal surface and does not enter through 
the basolateral surface. Adapted from Tsilingiri et al., Gut, 2012 [179] and Tsilingiri et al., JoVE, 
2013 [180]. 
 
3.9 Immunofluorescence and confocal microscopy 
 
Tissues were fixed overnight in 1% paraformaldehyde, 0.1 M L-Lysine pH 7.4 and 0.16% 
NaIO4 in P-buffer (0.02 M NaH2PO4 and 0.08 M Na2HPO4) pH 7.4. After washing in P-
buffer, tissues were dehydrated in 20% sucrose for at least 4h, included in optimum 
cutting temperature compound (Sakura Finetek) and frozen at -80º C. Ten μm-thick 
sections were cut, placed onto Superfrost Ultra Plus microscope slides (Thermo Scientific) 
and rehydrated with 0.1 M Tris-HCl pH 7.4. When staining for specific markers was 
performed, cryosections were blocked for 30 min with 2% FBS, 0.3% Triton X-100 in 0.1 
M Tris-HCl pH 7.4, followed by overnight incubation at 4ºC with the following primary 
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antibodies: polyclonal anti-MUC2 (Santa Cruz Biotechnology), polyclonal anti-
chromogranin A (Abcam), polyclonal anti-lysozyme (Dako). Cryosections were extensively 
washed before incubation at room temperature with the appropriate fluorophore-
conjugated secondary antibodies for 2h. Nuclei were counterstained with 4',6-diamidin-2-
fenilindolo (DAPI) and coverslips were applied after adding Vectashield mounting medium 
(Vectorlabs) on the cryosections. Confocal microscopy was performed on a Leica TCS 
SP5 laser confocal scanner mounted on a Leica DMI 6000B inverted microscope (Leica 
Microsystem) and images were acquired with a 40x or 63x oil immersion objective, using 
Leica Application Suite AF software (Leica Microsystem). Images were analyzed and 
processed using ImageJ software. 
 
3.10 Isolation of cells from small intestine lamina propria 
 
Small intestines from Cx3cr1GFP/+ mice were resected, cut longitudinally after removal of 
PP and connective tissue and extensively washed in PBS to eliminate feces. The tissue 
was cut in 1 cm pieces and incubated twice in separation medium (PBS, 10% FBS, 1 mM 
dithiothreitol, 1 mM ethylenediaminetetraacetic acid (EDTA)) for 15 min at 37°C and under 
gentle shaking to remove mucus. The tissue was then minced and incubated in digestion 
medium (Minimum Essential Medium α, 10% FBS, 0.5 mg/mL collagenase type VIII 
(Sigma-Aldrich), 5 U/mL DNase I (Roche Diagnostics), 100 IU/mL penicillin and 100 
μg/mL streptomycin) for 30 min at 37°C under gentle shaking. The obtained single cell 
suspension was passed through a strainer, to eliminate tissue debris, and centrifuged. 
Cells were washed in PBS, blocked with anti-FcR antibody (clone 24G2, BD Biosciences) 
and stained for flow cytometry with the following primary antibodies: anti-CD45.2 (clone 
104, BD Biosciences), CD11c (clone HL3, BD Pharmingen), IA/IE (clone M5/114.15.2, BD 
Biosciences), CD103 (clone M290, BD Pharmingen), CD11b (clone M1/70, BD 
Pharmingen). DAPI or Fixable Viability Stain (BD Biosciences) were added to exclude 
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dead cells. Samples were acquired using FACSCanto II (BD Biosciences) and analyzed 
with FlowJo software (Treestar).  
 
3.11 Isolation of cells from lymphoid organs 
 
PP were resected and digested in RPMI-1640 medium containing 10% FBS, 1 mg/mL 
collagenase D (Roche), 5 U/mL DNase I, 100 IU/mL penicillin and 100 μg/mL 
streptomycin for 20 min at 37°C. Spleens, mLN and the remaining tissue of PP were 
crushed onto a strainer with a syringe plunger to obtain a single cell suspension. Cells 
were centrifuged and, in the case of spleens, red blood cells were lysed with a hypotonic 
lysis buffer.  
When naïve CD4+ T cells were required for adoptive transfer experiments, spleens and 
lymph nodes from OT II mice were resected and cells were obtained as described above. 
Naïve CD4+ T cells were isolated using the CD4+ T Cell Isolation Kit (Miltenyi Biotec) 
together with biotinylated anti-CD25 antibody (Miltenyi Biotec), according to the 
manufacturer’s instructions. To obtain a higher purity, cells were passed twice in the 
separation column. Cells were labeled with 5 µM carboxyfluorescein succinimidyl ester 
(CFSE) for 10 min at 37ºC, followed by one wash in 10% FBS in PBS and extensive 
washing in PBS alone. Cell purity was evaluated by flow cytometry and typically ≥92% 
purity was achieved.  
When staining for flow cytometry was required, the obtained cell suspensions were 
incubated with anti-FcR antibody and stained with the following primary antibodies: anti-
CD45.2 (clone 104, BD Biosciences), CD45.1 (clone A20, eBioscience), CD3 (clone 145-
2C11, Biologend), CD4 (clone RM4-5, BD Pharmingen), CD62L (clone MEL14, BD 
Pharmingen), CD25 (clone PC61, BD Pharmingen). Fixable Viability Stain was added to 
exclude dead cells.  
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3.12 Staining for Tregs and cytokines 
 
For intracellular staining of Foxp3, surface staining was performed as described in section 
3.11, cells were fixed and permeabilized with Fix-Perm Buffer (eBioscience) and 
subsequently stained in Permeabilization Buffer (eBioscience) with anti-Foxp3 (clone FJK-
16s, eBioscience) antibody, following the manufacturer’s instructions. When detecting Th1 
and Th2 responses, cells were incubated in complete RPMI-1640 medium (10% FBS, 1% 
L-glutamine, 100 IU/mL penicillin and 100 μg/mL streptomycin) at 37ºC and stimulated for 
4h with 50 ng/mL phorbol myristate acetate (PMA, Sigma-Aldrich), 500 ng/mL ionomycin 
(Sigma-Aldrich) and 0.7 μL/mL Golgi Stop (BD Biosciences). Surface staining was 
performed as described in section 3.11, cells were fixed and permeabilized as above and 
intracellular cytokines were stained with anti-IFNγ (clone XMG1.2, BD Biosciences) and 
IL-4 (11B11, BD Biosciences) antibodies. 
 
3.13 Adoptive transfer and immunizations  
 
CFSE-labeled naïve CD4+ T cells from OT II mice, obtained as described in section 3.11, 
were transferred into C57BL/6-Ly5.1 mice by intravenous injection (2x106 cells/mouse). 
Mice were starved. The following day, NPL formulations or OVA alone were given to the 
recipients by intraduodenal injection or intragastric administration using a feeding needle, 
in a volume of 200 µL. When indicated, intragastric administration of NPL formulations 
was buffered with 5% NaHCO3.    
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3.14 Omeprazole treatment and GI tract pH measurement 
 
Mice were treated intragastrically with 200 µL Omeprazole (40 mg/Kg body weight, 
Sigma-Aldrich) diluted in 0.2% NaHCO3 and 0.5% methylcellulose. Untreated and treated 
mice were sacrificed, the stomach and intestine were excised and cut longitudinally, and 
the pH of their content was measured by placing a pH indicator stripe (GE Healthcare Life 
Sciences) on the mucosal surface of the tissues. 
 
3.15 Statistics 
 
Results are represented as mean±SEM. Statistical significance between two groups was 
determined by the unpaired Student's t-test. When more than two groups were compared, 
One-way ANOVA followed by Bonferroni post-test was performed. In all the cases, 
GraphPad Prism software was used to perform the statistical test. *p<0.05, **p<0.01, 
***p<0.001.  
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4 RESULTS 
 
4.1 Studies on the universal influenza vaccine candidate CTA1-
3M2e-DD 
 
4.1.1 Validation of CTA1-3M2e-DD targeting ability 
The influenza vaccine candidate CTA1-3M2e-DD has already been shown to elicit strong 
protective immunity against influenza virus challenge in mice as an intranasal vaccine 
[121,128]. Before assessing its potential as an oral vaccine, we performed in vitro binding 
experiments to confirm the targeting ability of CTA1-3M2e-DD in our hands. 
The adjuvant fusion protein CTA1-DD is able to bind to different Ig isotypes through the 
DD moiety, targeting splenic B cells in mice after intravenous injection [113]. Since CTA1-
3M2e-DD carries the same Ig-binding domain, we firstly assessed its targeting capability 
by incubating different amounts of fluorescently-labeled CTA1-3M2e-DD with mouse 
splenocytes, followed by staining for the B cell marker B220. Flow cytometric analysis 
revealed that CTA1-3M2e-DD binds to mouse splenic B cells, in a dose-dependent 
manner (Fig. 4.1).    
The targeting of human B cells by CTA1-DD was also previously reported [181]. Similarly, 
when incubating human PBMCs with CTA1-3M2e-DD conjugated with AF488, we 
observed a dose-dependent binding of this fusion protein to CD19+ B cells (Fig. 4.2). 
Moreover, as shown for CTA1-DD binding to human B cells by Eriksson and Lycke [181], 
CTA1-3M2e-DD also exhibited a bimodal binding pattern to this cell population in our 
assays, with one subpopulation of CD19+ cells showing higher fluorescence and another 
CD19+ subpopulation showing lower fluorescence (Fig. 4.2).  
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Figure 4.1. CTA1-3M2e-DD binds to mouse splenic B cells.  
Flow cytometric analysis of the binding ability of CTA1-3M2e-DD/AF488 to freshly isolated 
splenocytes from C57BL/6 mice after 1h of incubation with the indicated amounts of fusion protein 
(µg), followed by staining for a B cell marker (B220). Histogram representations show AF488 
fluorescence intensity of B220+ cells in the presence (colored histograms) or absence (shaded 
histogram) of CTA1-3M2e-DD. The geometric mean fluorescence intensity for each condition is 
reported inside the histograms. Data are representative of two independent experiments.  
 
Figure 4.2. CTA1-3M2e-DD binds to human B cells.  
Flow cytometric analysis of the binding ability of CTA1-3M2e-DD/AF488 to freshly isolated human 
PBMCs after 1h of incubation with the indicated amounts of fusion protein (µg), followed by staining 
for a B cell marker (CD19). Histogram representations show AF488 fluorescence intensity of 
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CD19+ cells in the presence (colored histograms) or absence (shaded histogram) of CTA1-3M2e-
DD. The geometric mean fluorescence intensity for each condition is reported inside the 
histograms. Data are representative of two independent experiments.  
 
We therefore confirmed that the targeting function of the DD region is maintained in the 
influenza vaccine candidate CTA1-3M2e-DD, based on what was previously published for 
the fusion protein CTA1-DD. 
 
4.1.2 Characterization of CTA1-3M2e-DD uptake in the small intestine 
One of the most challenging aspects of designing mucosal vaccines is overcoming the 
harsh environment that they will encounter: degradation by proteases in mucosal 
secretions, entrapment by gel-forming mucins, and exclusion by epithelial barriers are 
some examples. When exploring the GI tract as a potential immunization route for a new 
vaccine, it is important to understand whether it can escape these hurdles and be 
available to immune cells. 
We continued our studies by investigating whether CTA1-3M2e-DD, as an oral vaccine, 
can reach the lamina propria of the small intestine and be accessible to APCs. In order to 
do so, and at the same time avoid degradation by gastric enzymes and dilution throughout 
the GI tract, but still mimicking an oral immunization, CTA1-3M2e-DD was directly 
administered in the small intestine. C57BL/6 mice were subjected to intestinal ligation and 
different amounts of CTA1-3M2e-DD conjugated with AF647 were injected into the 
intestinal loops. Two hours later, the loop was resected and processed for imaging 
analysis. 
As depicted in Figure 4.3, administration of increasing doses of CTA1-3M2e-DD/AF647 in 
ligated intestinal loops revealed that high amounts of protein were required for its 
detection, as only intestinal loops treated with 100 µg of CTA1-3M2e-DD/AF647 allowed a 
clear visualization of the fusion protein. Regarding CTA1-3M2e-DD localization, 2h after  
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Figure 4.3. CTA1-3M2e-DD remains in the intestinal lumen 2h after administration.  
The small intestine of C57BL/6 mice was exposed, an intestinal loop was formed and the indicated 
amounts of CTA1-3M2e-DD conjugated with AF647 or PBS (vehicle) were injected into the loop. 
Two hours later, the loop was resected and processed for confocal microscopy. Cryosections were 
stained with DAPI. Confocal images of intestinal villi showing CTA1-3M2e-DD (red) and nuclei 
(blue). n=3 mice/group. Scale bars: 50 µm.  
 
injection, the fusion protein remained in the intestinal lumen, surrounding the epithelium, 
and did not reach the lamina propria.   
 
4.1.3 Characterization of CTA1-3M2e-DD uptake by intestinal APCs 
Although CTA1-3M2e-DD failed to cross the intestinal epithelial barrier after 2h of its 
administration, we wondered if the fusion protein could still target intestinal APCs present 
in the small intestine lamina propria after an extended period of treatment.  
To evaluate which subset of lamina propria APCs was able to take up CTA1-3M2e-DD, 
we took advantage of Cx3cr1GFP/+ mice. These heterozygous knock-in mice carry a gene 
coding for GFP under the control of the CX3CR1 promoter [175], allowing us to efficiently 
distinguish CX3CR1+ cells, a marker used to discriminate an important subset of 
macrophages in the small intestine, which otherwise would be difficult as the commercially 
available antibodies for CX3CR1 have proven to be far from effective. Cx3cr1GFP/+ mice 
were administered 100 µg of CTA1-3M2e-DD/AF647 (or vehicle alone) through 
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intraduodenal injection and 4h later the entire small intestine was collected and processed 
for flow cytometric analysis in order to quantify the uptake of CTA1-3M2e-DD.  
The expression of CX3CR1 and CD103 is typically used to identify the two main APC  
subsets in the small intestine, CX3CR1+ macrophages and CD103+ DCs. Thus, the cells 
isolated from small intestines were stained with antibodies for CD45.2, IA-IE, CD11c, 
CD103 and CD11b. As shown in Figure 4.4, after excluding dead cells and gating 
CD45.2+ IA-IE+ CD11c+ cells, the two main APC subsets were distinguished through their 
expression of CX3CR1 and CD103. CX3CR1+ macrophages were further divided based on 
their intermediate and high expression of CX3CR1 (CX3CR1int and CX3CR1high, 
respectively). Gating on CD103+ DCs and separating them by their expression of CD11b 
allowed us to identify two other subsets, CD103+ CD11b- and CD103+ CD11b+. 
 
 
Figure 4.4. Gating strategy to define the main subsets of APCs in the small intestine lamina 
propria.  
The small intestine of a Cx3cr1GFP/+ mouse was processed to obtain a single-cell suspension. Cells 
were stained with a viability marker and antibodies for CD45.2, CD11c, IA-IE, CD103 and CD11b, 
and subsequently analyzed by flow cytometry. After exclusion of dead cells and epithelial cells 
(CD45.2-), IA-IE+ CD11c+ cells were gated and three APC subsets can be identified: CD103+ DCs, 
CX3CR1int and CX3CR1high macrophages. CD103+ cells were further divided based on their 
expression of CD11b, distinguishing CD103+ CD11b- and CD103+ CD11b+ DC populations.   
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Figure 4.5. CTA1-3M2e-DD is poorly taken up by small intestine lamina propria APCs.  
PBS (vehicle) or 100 µg of CTA1-3M2e-DD/AF647 were injected in the duodenum of Cx3cr1GFP/+ 
mice. After 4h, the small intestines were processed and cells were isolated for flow cytometric 
analysis. (A) Representative dot plots show the percentage of CTA1-3M2e-DD+ cells found in 
CD45.2- cells and in each subset of APCs. (B) Percentage of CTA1-3M2e-DD+ cells in CX3CR1high, 
CX3CR1int, CD103+ CD11b- and CD103+ CD11b+ subsets. Data are shown as mean±SEM and are 
representative of two independent experiments, n=3 mice/group.  
 
Four hours following CTA1-3M2e-DD administration, we observed that the protein was 
mainly associated with CD45.2- cells, most likely intestinal epithelial cells (Fig. 4.5A). In 
the different subsets of APCs that were analyzed, only a small percentage of CTA1-3M2e-
DD+ cells were found in CX3CR1high macrophages, while the fusion protein was virtually 
absent in the remaining subsets (Fig. 4.5A-B).  
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These results suggest that CD45.2- epithelial cells are a major contributor for CTA1-3M2e-
DD uptake in the small intestine. However, and based on our initial observation through 
imaging analysis, due to the retention of the protein in the lumen and attachment to the 
luminal surface of the epithelium for at least 2h after administration, CTA1-3M2e-DD+ 
CD45.2- cells observed by flow cytometry can reflect surface association and not 
necessarily internalization of the protein by epithelial cells. The fact that CTA1-3M2e-DD 
was found associated with CX3CR1high phagocytes, which are endowed with the ability of 
extending trans-epithelial dendrites [49], might indicate the direct uptake of the protein by 
this population. 
 
4.2 Studies on the vaccine delivery system NPL 
4.2.1 Characterization of NPL uptake in the small intestine  
Given the low capacity of CTA1-3M2e-DD to penetrate the intestinal barrier and target 
APCs in the lamina propria, we turned our attention to the nanoparticle-based vaccine 
vectors that are being developed in our consortium to achieve enhanced targeting of 
immune cells in mucosal tissues. Cationic polysaccharide nanoparticles with a lipidic core, 
NPL, have already been characterized [182] and tested as vaccine vectors for mucosal 
immunization, namely intranasal delivery of vaccines [177]. Thus, we decided to 
investigate the behavior of NPL as a potential vaccine delivery system for oral vaccines. 
To understand whether NPL could overcome the different components of the intestinal 
barrier, and identically to what was done with the influenza vaccine candidate, we 
performed intestinal loops in C57BL/6 mice, injected 50 µg of FITC-labeled NPL and 
analyzed their uptake by confocal microscopy. 
After only 1h of its administration, NPL crossed the epithelial barrier in the intestine, as we 
were able to visualize them not only in the lumen, but also filling a few epithelial cells 
(highlighted by filled arrowheads) and most importantly in the lamina propria (highlighted 
by empty arrowheads) (Fig. 4.6). 
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Figure 4.6. NPL cross the intestinal epithelium and reach the mouse intestinal lamina 
propria.  
The small intestine of C57BL/6 mice was exposed and 50 µg of NPL/FITC or PBS (vehicle) were 
injected into an intestinal loop. After 1h, the loop was resected and processed for confocal 
microscopy. Cryosections were stained with DAPI. Confocal images of intestinal villi showing NPL 
(green) and nuclei (blue). Filled arrowheads and empty arrowheads highlight localization of NPL 
within epithelial cells and in the lamina propria, respectively. Images are representative of two 
independent experiments, n=3-4 mice/group. Scale bars: 50 µm.  
 
Since the goal of our consortium is to generate a human influenza vaccine, we questioned 
whether NPL were also taken up in the human intestine. We took advantage of an ex vivo 
organ culture model developed a few years ago in our group to study the human intestine 
[179,180]. This model allows studying the response of intestinal tissue in a way that 
resembles the physiologic situation, as the polarization of the tissue is maintained and the 
stimulus of interest is solely in contact with the luminal surface and does not reach the 
basolateral side. Explants of human intestine (ileum) were cultured and, after allowing 
mucus reconstitution for 1h in order to mimic the in vivo situation, 20 µg of NPL/FITC or 
medium alone (vehicle) were added to the luminal surface of the tissue for another hour. 
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Figure 4.7. NPL cross the epithelium and reach the lamina propria in an ex vivo human 
intestine culture model.  
Explants of human ileum were fixed upon arrival (not treated, NT) or were maintained in culture 
with 20 µg of NPL/FITC or medium alone (vehicle) in contact with the luminal surface for 1h. The 
cultured explants were then processed for confocal microscopy and cryosections were stained with 
DAPI. Confocal images of intestinal villi showing NPL (green) and nuclei (blue). Filled arrowheads 
and empty arrowheads highlight localization of NPL within epithelial cells and in the lamina propria, 
respectively. Representative images of four surgically resected ileal specimens. Scale bars: 50 µm.  
 
Confocal analysis showed that the culture process did not affect tissue integrity, by 
comparing the villi morphology in cultured explants with the same in a piece of the 
specimen that did not undergo culture and was immediately fixed upon arrival (Fig. 4.7). 
Similarly to what was found in vivo in mice, NPL crossed the epithelial barrier in the 
human intestine, with NPL found within some epithelial cells (highlighted by filled 
arrowheads) and concentrated in the lamina propria (highlighted by empty arrowheads). 
We therefore validated the ability of NPL to cross epithelial barriers in two different models 
(mouse and human) that enable us to study their behavior as a vaccine delivery system 
for oral immunization. 
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4.2.2 Identification of NPL-filled intestinal epithelial cells 
Depending on the size and nature of intestinal antigens, these are sampled from the 
lumen and transferred into the lamina propria by different mechanisms [81]. Some of 
these mechanisms depend on intestinal epithelial cells that are specialized precisely in 
antigen sampling, particularly M cells [80–82,84,86,87,89]. However, epithelial cells with 
other functions, such as enterocytes that are specialized in nutrient absorption or Goblet 
cells that produce and secrete mucins, may also contribute to antigen transfer into the 
lamina propria or directly to specific immune cells [90,92,183].  
High amounts of NPL were found within some epithelial cells in the intestines of mice (Fig. 
4.6) and human intestinal explants (Fig. 4.7). These cells are unlikely to be enterocytes, 
as these are the most abundant epithelial cells in the intestine and we observed NPL+ 
epithelial cells with much less frequency in our experiments. Because these cells seem to 
facilitate the entrance of NPL into the lamina propria, we proceeded with their 
identification. Cryosections from intestinal loops of C57BL/6 mice treated with 50 µg of 
NPL/FITC for 1h were stained with antibodies for markers of different epithelial cells that 
exist in the epithelium at low frequencies. These epithelial cells include mucus-secreting 
Goblet cells, identified by the presence of MUC2; Paneth cells, identified by lysozyme 
(LYS), one of the antimicrobial enzymes secreted by these cells in the intestinal crypts; 
and enteroendocrine cells, which production of the neuroendocrine protein chromogranin 
A (CmgA) allows its visualization. 
As shown in Figure 4.8, the distribution of NPL in the distinct mouse intestinal epithelial 
cells varies greatly. We found that small clusters of NPL were present inside LYS+ Paneth 
cells, whereas CmgA+ enteroendocrine cells did not take up NPL. Nonetheless, the cells 
initially detected as entry passages for NPL were identified as MUC2+ Goblet cells, as this 
marker co-localizes with the presence of high amounts of NPL in the epithelium. 
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Figure 4.8. Goblet cells in the mouse small intestine transfer high amounts of NPL into the 
lamina propria.  
Intestinal loops of C57BL/6 mice were injected with 50 µg of NPL/FITC and resected 1h later, 
followed by tissue processing for confocal microscopy. Cryosections were stained with DAPI and 
antibodies against different epithelial cell markers: MUC2 for Goblet cells; CmgA for 
enteroendocrine cells; LYS for Paneth cells. Confocal images of intestinal villi show NPL (green), 
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nuclei (blue) and the different epithelial cells (red). Square inset is shown on the right of each 
image with single channels for NPL and the different epithelial cells. Dashed lines represent the 
contour of NPL-filled epithelial cells and/or epithelial cells identified by each marker. Images are 
representative of two independent experiments, n=3-4 mice/group. Scale bars: 10 µm. 
 
As NPL were also visualized within a few epithelial cells of human intestinal explants 
following our ex vivo experiments for NPL uptake, we wondered if these NPL+ cells were 
also Goblet cells. Cryosections from explants cultured with 20 µg of NPL/FITC for 1h were 
consequently stained for MUC2. In accordance to what was found in the mouse intestinal 
epithelium, NPL co-localized with MUC2+ cells in the epithelium of the human intestine 
(Fig. 4.9). 
 
 
Figure 4.9. Goblet cells in the human intestine transfer high amounts of NPL into the lamina 
propria.  
Explants of human ileum were maintained in culture with 20 µg of NPL/FITC in contact with the 
luminal surface for 1h, followed by tissue processing for confocal microscopy. Cryosections were 
stained with DAPI and anti-MUC2 antibody. Confocal images of intestinal villi showing NPL (green), 
nuclei (blue) and MUC2 (red). Square inset is shown on the right of the image with single channels 
for NPL and MUC2. Dashed line represents the contour of a MUC2+ Goblet cell transferring NPL. 
Representative images of four surgically resected ileal specimens. Scale bars: 10 µm. 
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Together, these results suggest that Goblet cells are a major contributor in the intestinal 
epithelium for NPL uptake and transfer from the lumen to the lamina propria. 
 
4.2.3 Characterization of NPL uptake by intestinal APCs 
Taking into account that NPL succeeded in traversing the epithelial barrier at the level of 
the intestine and were found in the lamina propria (where they were available for 
phagocytosis by immune cells), as shown by imaging analysis, we next wondered which 
intestinal APCs were able to take up NPL.  
 
 
Figure 4.10. NPL are taken up by different subsets of intestinal lamina propria APCs.  
PBS (vehicle) or 250 µg of NPL/DiD were administered to Cx3cr1GFP/+ mice through intraduodenal 
injection. Two hours later, the small intestines were processed and cells were isolated for flow 
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cytometric analysis. (A) Representative dot plots show the percentage of NPL+ cells found in 
CD45.2- cells and in each subset of APCs. (B) Percentage of NPL+ cells in CX3CR1high, CX3CR1int, 
CD103+ CD11b- and CD103+ CD11b+ subsets. Data are shown as mean±SEM and are 
representative of two independent experiments, n=3-4 mice/group.  
 
Once more, we identified the main subsets of APCs by flow cytometric analysis (Fig. 4.4) 
and quantified the uptake of DiD-labeled NPL in the small intestine lamina propria of 
Cx3cr1GFP/+ mice 2h after its administration directly in the duodenum. NPL were present in 
CD45.2- cells, presumably epithelial cells, which confirms our results from confocal 
microscopy analysis, but, most importantly, they were distributed across all the main APC 
subsets (Fig. 4.10A). The four analyzed subsets were able to internalize NPL to different 
extents, with CX3CR1+ macrophages showing a slightly higher percentage of NPL+ cells 
than CD103+ DCs (Fig. 4.10B). 
The previous findings further support the aptness of NPL as vaccine carriers for oral 
delivery, as they are able not only to cross the intestinal epithelial barrier, but also target 
different types of intestinal APCs. 
 
4.2.4 NPL uptake by CX3CR1+ macrophages 
 From the previous results, we determined that NPL are transferred to the lamina propria 
through Goblet cells, where different APCs internalize them. One of these subsets of 
APCs, CX3CR1+ macrophages, have the capacity to directly acquire antigens from the 
intestinal lumen by extending protrusions across the epithelium [49]. We therefore asked 
whether the uptake of NPL by these cells was also a result of this feature. 
To answer that, we injected 50 µg of NPL/DiD into intestinal loops of Cx3cr1GFP/+ mice and 
processed the tissue for confocal microscopy in order to visualize the possible formation 
of trans-epithelial protrusions by CX3CR1+ cells. As depicted in Figure 4.11, we confirmed 
the localization of NPL within CX3CR1+ cells, 1h after NPL administration, but no CX3CR1+ 
protrusions were found at the level of the villi. When looking at PP, however, NPL were  
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Figure 4.11. CX3CR1+ cells in PP directly acquire NPL from the lumen.  
The small intestine of Cx3cr1GFP/+ mice was exposed and 50 µg of NPL/DiD were injected into an 
intestinal loop containing a PP. After 1h, the loop was resected and processed for confocal 
microscopy. Cryosections were stained with DAPI. Confocal images of intestinal villi and PP 
showing CX3CR1 (green), NPL (red) and nuclei (blue). Single channels for DAPI, CX3CR1 and NPL 
are shown on the right of each image. Arrowheads highlight localization of CX3CR1+ cells or their 
protrusions crossing the FAE. Images are representative of two independent experiments, n=3 
mice/group. Scale bars: 10 µm.  
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also found within CX3CR1+ cells and their dendrites or even the entire cell body was 
visualized crossing the FAE and sampling NPL from the lumen (highlighted by 
arrowheads).  
This confirms that, at least in PP, the uptake of NPL by CX3CR1+ macrophages occurs 
directly and not merely due to epithelial transfer of NPL.  
 
4.2.5 Characterization of antigen delivery by NPL in the small intestine  
Vaccine delivery systems should be able to protect the vaccine against degradation and 
release it in the target tissue or cell. Studies have shown that loading NPL with OVA as a 
model antigen and giving this formulation by intranasal administration in mice extends the 
time of residence of the protein in the nose as compared to administering the protein 
alone [177]. 
To test the ability of NPL to protect the loaded antigen in the intestine and deliver it in the 
lamina propria, we used NPL and OVA in formulation, each conjugated with different 
fluorochromes. C57BL/6 mice were then treated with this formulation through injection in 
intestinal loops and the distribution of both OVA and NPL was visualized by confocal 
microscopy. Similarly to what was observed before in experiments with NPL alone, we 
were able to visualize some epithelial cells filled with OVA:NPL, as well as clusters of the 
formulation inside the lamina propria (highlighted by yellow arrowheads) (Fig. 4.12). 
Nevertheless, OVA alone was also found in epithelial cells and lamina propria (highlighted 
by white arrowheads). 
This suggests that NPL can protect the formulated antigen from intestinal degradation, but 
probably a mechanism of antigen-NPL dissociation takes place when the vaccine vector is 
transferred through the epithelium, delivering some of the antigen by itself. 
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Figure 4.12. Antigen loaded into NPL reaches the lamina propria both in free form and 
associated with the vaccine vector.  
Intestinal loops were performed in C57BL/6 mice and NPL/FITC loaded with OVA/TRITC (10 µg 
OVA:50 µg NPL) were injected in the loop. One hour later, the tissue was resected and processed 
for confocal microscopy. Cryosections were stained with DAPI. Confocal images of intestinal villi 
showing NPL (green), OVA (red) and nuclei (blue). Single channels for DAPI, NPL and OVA are 
shown on the right of the image. White and yellow arrowheads indicate localization of OVA alone 
and OVA:NPL, respectively. Filled and empty arrowheads highlight localization of the latter in 
epithelial cells and lamina propria, respectively. n=3 mice. Scale bars: 10 µm. 
 
4.2.6 Effect of starvation and immunization time in the immune response of 
OVA:NPL treated mice 
We next evaluated if formulating an antigen with NPL would be advantageous for antigen 
delivery/presentation in the small intestine, compared to administration of the antigen 
alone. We assessed that by choosing OVA as a model antigen and taking advantage of 
OT II mice, that express a transgenic T cell receptor able to recognize OVA323-339 when 
presented by IA-IE on APCs. This allows us to measure and compare antigen-specific T 
cell activation after presentation of the antigen when this is delivered alone or formulated 
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with the vaccine vector. Thus, we isolated naïve CD4+ T cells from lymphoid organs of OT 
II (Ly5.2) mice and, after labeling them with CFSE (that enables the measurement of cell 
proliferation, as it is equally distributed by daughter cells when cells divide), they were 
transferred into C57BL/6 (Ly5.1) mice through intravenous injection (Fig. 4.13). The next 
day, recipient mice were immunized with NPL alone (no antigen), OVA alone or OVA 
formulated with NPL by intraduodenal injection. Five days later, different organs were 
collected from the immunized mice and we assessed CD4+ T cell proliferation in the OVA-
specific Ly5.2+ population by flow cytometry. 
We observed that NPL-immunized mice showed virtually no proliferation in this cell 
population, as expected, as no antigen was present, whereas mice immunized with OVA 
alone or in combination with NPL presented higher proliferation (Fig 4.14). When 
comparing the OVA and OVA:NPL immunized groups, no significant advantage was given 
by the formulated treatment. However, we noticed that proliferation of OVA-specific CD4+ 
T cells in the group receiving OVA:NPL reflected high variability. 
 
 
Figure 4.13. Scheme of the adoptive transfer and immunization schedule.  
Spleens and lymph nodes from OT II Ly5.2 mice were collected and CD25- CD4+ T cells were 
isolated. After labeling with CFSE, these cells were transferred into C57BL/6-Ly5.1 mice (2x106 
cells/mouse) through intravenous injection. The following day, the recipient mice were immunized 
and 5 days later organs were collected, processed for flow cytometry and OVA-specific CD4+ T cell 
proliferation was evaluated as CFSE dilution.  
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Figure 4.14. In vivo proliferation of antigen-specific CD4+ T cells after immunization with 
NPL formulation.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to intraduodenal immunization with NPL alone (1 mg), OVA (200 µg) or 
formulation OVA:NPL (200 µg OVA:1 mg NPL). Five days later, proliferation of OT II Ly5.2+ CD4+ T 
cells in indicated organs was measured by flow cytometry. Each data point represents an individual 
mouse. Data are shown as mean±SEM, n=3-5 mice/group. One-way ANOVA followed by 
Bonferroni test was used to evaluate statistical significance. *p<0.05. 
 
Since immunization relied on a procedure that takes some time to perform, as it includes 
subjecting the mice to anesthesia, surgery and intraduodenal injection, we hypothesized 
that this variability could be explained by different times of immunization. Accordingly, we 
plotted the percentage of OT II CD4+ proliferating T cells from this experiment with the 
time at which the immunization occurred for each mouse (Fig. 4.15). Indeed, from these 
preliminary results, we noticed a trend in the group immunized with OVA:NPL, in which 
mice subjected to immunization in the morning presented lower percentage of antigen-
specific proliferating cells than mice from the same group immunized in the afternoon. In 
the case of OVA-treated mice, the immunization occurred in a shorter window of time and 
this trend couldn’t be confirmed. 
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Figure 4.15. OVA-specific CD4+ T cell proliferation according to the time of immunization. 
The percentage of OVA-specific CD4+ proliferating T cells presented in Figure 4.14 was plotted 
against the corresponding immunization time for each mouse. Each data point represents an 
individual mouse.  
 
Based on these preliminary results, we thought about two possible factors that could 
influence the outcome of the immune response in this setting. In order to decrease the 
intestinal content, so it does not pose an important source of material competing with the 
immunization treatment, in our experiments the food is removed from the cages the 
evening before immunization. This means that mice undergo starvation during the night 
and until the moment of immunization and the ones that receive the treatment in the 
morning are less starved than the ones receiving it in the afternoon. As such, the period of 
starvation before immunization could play an important role. The other possibility is that 
the time of immunization itself shapes the immune response and mice immunized in the 
afternoon show a better response than the ones immunized in the morning. 
Before deepening the investigation on the advantage of antigen presentation when it is 
formulated with NPL and to obtain more reliable results (addressed in sections 4.2.7 and 
4.2.8), we decided to understand if the two factors mentioned above could really impact 
our experiments, in order to exclude this source of variability. We therefore uncoupled 
these two factors, immunization time and starvation, and evaluated the individual 
contribution of each. 
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Figure 4.16. Effect of immunization time on the immune response after OVA:NPL 
immunization.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to intraduodenal immunization with OVA:NPL (200 µg OVA:1 mg NPL) in the 
morning (around 10 am) or in the afternoon (around 1 pm) without previous starvation. Five days 
later, the immune response in the OT II Ly5.2+ CD4+ T cell population of the indicated organs was 
analyzed by flow cytometry. (A) Percentage of proliferating OT II CD4+ T cells. (B) Percentage of 
Foxp3+ cells in OT II CD4+ T cells. Each data point represents an individual mouse. Data are 
shown as mean±SEM, n=5 mice/group. Unpaired Student’s t-test was used to evaluate statistical 
significance. 
 
To understand the role of immunization time, we performed a similar experiment without 
previous starvation and immunizing the mice with OVA:NPL (the treatment in which we 
observed variability). In one group of mice, immunization occurred in a short window of 
time in the morning (around 10 am), whereas the other group of mice was immunized in 
the afternoon (around 1 pm). By assessing the proliferation of OVA-specific CD4+ T cells 
in spleens, mLN and PP, we determined that the immunization time alone was not 
modulating the immune response, as T cell activation in both groups was comparable 
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(Fig. 4.16A). Additionally, we also performed staining for Foxp3 on these cells in order to 
understand if morning or afternoon immunizations could influence Treg cell conversion 
and therefore tolerance induction. Similarly, time of immunization did not significantly 
affect the occurrence of OVA-specific Tregs (Fig. 4.16B). 
 
 
Figure 4.17. Effect of starvation on the immune response after OVA:NPL immunization.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to intraduodenal immunization with OVA:NPL (200 µg OVA:1 mg NPL) after 
previous starvation during a long (19h) or short (16h) period. Five days later, the immune response 
in the OT II Ly5.2+ CD4+ T cell population of the indicated organs was analyzed by flow cytometry. 
(A) Percentage of proliferating OT II CD4+ T cells. (B) Percentage of Foxp3+ cells in OT II CD4+ T 
cells. Each data point represents an individual mouse. Data are shown as mean±SEM and are 
pooled from four independent experiments. Unpaired Student’s t-test was used to evaluate 
statistical significance. *p<0.05. 
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The sole contribution of the starvation period was subsequently assessed. To do so, a 
group of mice was immunized after 16h of starvation (short starvation) and another group 
after 19h (long starvation) (the duration of starvation of mice showing lower and higher 
proliferation, respectively, in the preliminary experiment, Fig. 4.15), and immunization with 
OVA:NPL occurred at random time of the day. Interestingly, we observed that long 
starvation induced significantly higher proliferation of OT II CD4+ T cells in spleen and 
mLN, with PP showing a similar trend (Fig. 4.17A). Despite the increase in antigen 
presentation, a long starvation period did not induce Tregs in this population in any of the 
analyzed organs (Fig. 4.17B). 
 
 
Figure 4.18. Combined effect of starvation and immunization time on the immune response 
after OVA:NPL immunization.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to intraduodenal immunization in the morning (around 10 am) or afternoon 
(around 1 pm) with OVA:NPL (200 µg OVA:1 mg NPL) after previous starvation during a long (19h) 
or short (16h) period. Five days later, the immune response in the OT II Ly5.2+ CD4+ T cell 
population of the indicated organs was analyzed by flow cytometry. (A) Percentage of proliferating 
OT II CD4+ T cells. (B) Percentage of Foxp3+ cells in OT II CD4+ T cells. Each data point 
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represents an individual mouse. Data are shown as mean±SEM and are pooled from two 
independent experiments. One-way ANOVA followed by Bonferroni test was used to evaluate 
statistical significance.  
  
Finally, we sought to understand if both starvation period and immunization time could 
have a combinatorial effect on this setting. We immunized (with OVA:NPL) a group of 
mice in the morning and another in the afternoon, and further divided each group by the 
starvation period that each underwent, either long or short. As shown in Figure 4.18A, the 
four groups presented comparable OVA-specific CD4+ T cell activation in spleen, mLN 
and PP, and no specific immunization time-starvation period combination resulted in a 
different response. Noteworthy, the effect of starvation was noticed here too, as groups 
immunized at different time of the day and under long starvation showed a trend to 
present higher proliferation than their counterpart. Again, Tregs in the OT II CD4+ T cell 
population were not affected by the different combinations of immunization time-starvation 
period, as similar percentages of Foxp3+ CD4+ T cells were found in all tissues (Fig. 
4.18B). 
We determined that, from the possible factors, according to our data, that could affect the 
outcome of the immune response in this immunization setting, starvation plays an 
important role and should be considered to avoid artifacts in this types of experiments. 
 
4.2.7 NPL enhance antigen presentation without establishment of oral 
tolerance 
Acknowledging the important effect of starvation, we proceeded our investigation on the 
function of NPL as an oral vaccine vector. Using the same experimental setting, but 
performing the immunization to all the differently treated groups under the same starvation 
period (19h), we compared the OVA-specific CD4+ T cell response in mice immunized 
with NPL, OVA and OVA:NPL. Five days after immunization, a significantly higher 
percentage of OT II CD4+ proliferating T cells was found in the spleen and mLN of mice 
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receiving OVA formulated with NPL, relatively to the group receiving OVA alone (Fig. 
4.19A). The same was not observed in PP, as both treatments induced similar 
proliferation of this T cell population. When looking at the OVA-specific Foxp3+ CD4+ T cell 
population, no conversion of Tregs was observed in the different treatments, despite the 
greater antigen presentation in OVA:NPL immunized mice (Fig. 4.19B). 
 
 
Figure 4.19. Advantage of NPL formulation in antigen-specific CD4+ T cell response after 
immunization.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to intraduodenal immunization with NPL alone (1 mg), OVA (200 µg) or 
formulation OVA:NPL (200 µg OVA:1 mg NPL) after previous starvation during a long (19h) period. 
Five days later, the immune response in the OT II Ly5.2+ CD4+ T cell population of the indicated 
organs was analyzed by flow cytometry. (A) Percentage of proliferating OT II CD4+ T cells. (B) 
Percentage of Foxp3+ cells in OT II CD4+ T cells. Each data point represents an individual mouse. 
Data are shown as mean±SEM and are pooled from five independent experiments (in the case of 
spleens and mLN) or four independent experiments (in the case of PP). One-way ANOVA followed 
by Bonferroni test was used to evaluate statistical significance. *p<0.05, **p<0.01, ***p<0.001.  
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 Altogether, this suggests that NPL have the potential to increase presentation of the 
loaded antigen without prompting tolerance, two fundamental aspects of a successful 
vaccine.  
 
4.2.8 Antigen delivery by NPL induces a Th1 response in PP 
 
 
Figure 4.20. Th1 and Th2 immune responses after immunization with NPL formulation.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to intraduodenal immunization with NPL alone (1 mg), OVA (200 µg) or 
formulation OVA:NPL (200 µg OVA:1 mg NPL) after previous starvation during a long (19h) period. 
Five days later, the cytokine production ability in the OT II Ly5.2+ CD4+ T cell population of the 
indicated organs was analyzed by flow cytometry, after in vitro stimulation with PMA and ionomycin 
for 4h. (A) Percentage of IFNγ-producing cells in the OT II CD4+ T cell population. (B) Percentage 
of IL-4-producing cells in the OT II CD4+ T cell population. Each data point represents an individual 
mouse. Data are shown as mean±SEM and are pooled from two independent experiments. One-
way ANOVA followed by Bonferroni test was used to evaluate statistical significance. **p<0.01, 
***p<0.001.  
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Since immunization with particulate adjuvants often results in enhanced protective 
immune responses, we questioned whether NPL have such ability. Immunization with 
NPL, OVA or OVA:NPL was performed on mice under long starvation in the same 
experimental setting. At the time of analysis, cells from spleen, mLN and PP were isolated 
and stimulated in vitro with PMA and ionomycin, and IFNγ- and IL-4-producing cells in the 
OT II CD4+ T cell population was quantified by flow cytometry. As depicted in Figure 
4.20A, the percentage of OVA-specific CD4+ T cells able to produce IFNγ in PP was 
significantly higher when mice were immunized with OVA formulated with NPL than with 
the antigen alone. This Th1 response was only observed in this tissue though, as in 
spleen and mLN the IFNγ-producing population was similar between all groups. As for IL-
4 production, no real difference was observed between the different immunization groups 
(Fig. 4.20B). 
 
4.2.9 Protection of NPL from the stomach acidic pH 
One of the main challenges when dealing with oral vaccines is maintaining their stability 
throughout the GI tract, as great pH fluctuations are present and digestive enzymes can 
also modify them. The stomach, in particular, poses one of the biggest threats with its 
extremely acidic pH. The stability of NPL formulations in the stomach were next 
evaluated. During our investigation, we adopted the intraduodenal administration as a 
surrogate for oral immunization so we could study both the vaccine and NPL without the 
putative degradation/modification in the stomach. Taking advantage of the experimental 
setting used in the previous studies, and having validated the vaccine vector function of 
NPL in increasing the immune response towards the loaded antigen, we tested whether 
this function is maintained when its administration was closer to an oral immunization, i.e. 
through intragastric administration. 
As shown in Figures 4.21A and B, the advantage of NPL formulation was completely 
abrogated when OVA:NPL was administered in the stomach, showing similar percentages 
of OVA-specific CD4+ T cell proliferation to what was found in mice immunized with OVA  
72 
 
 
Figure 4.21. Comparison of antigen-specific CD4+ T cell response after intraduodenal and 
intragastric immunization.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to immunization by intraduodenal injection or intragastric administration with 
NPL alone (1 mg), OVA (200 µg) or formulation OVA:NPL (200 µg OVA:1 mg NPL) after previous 
starvation during a long (19h) period. Five days later, the immune response in the OT II Ly5.2+ 
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CD4+ T cell population of the indicated organs was analyzed by flow cytometry. (A) Representative 
histograms showing cell division of OT II CD4+ T cells in the different treatment groups and the 
respective percentage of CFSElow cells. (B) Percentage of proliferating OT II CD4+ T cells. (C) 
Percentage of Foxp3+ cells in OT II CD4+ T cells. Each data point represents an individual mouse. 
Data are shown as mean±SEM, n=3 mice/group.  
 
alone given intragastrically or even when the antigen was absent. The percentage of 
OVA-specific Treg cells did not seem to vary between differently immunized groups either 
by intraduodenal injection or intragastric administration in both organs (Fig. 4.21C), the 
only exception being the spleen, in which less Tregs were found in the groups immunized 
intragastrically with OVA and OVA:NPL compared with OVA:NPL immunized mice by 
injection in the duodenum. Still, this difference does not indicate that more OVA-specific 
Tregs are induced by OVA in formulation and delivered by intraduodenal injection, as the 
percentage of this cell population in this group is similar to the one found when OVA is not 
present. However, due to the reduced number of mice in each group, a statistical analysis 
was not performed and no significant differences between the different groups can be 
inferred. Despite the reduced number of mice, it was clear though through this experiment 
that administration of NPL formulation by oral gavage puts at risk its vaccine vector 
function, our main question in this experiment. 
Trying to overcome the effect of the environment of the stomach, in order to protect NPL 
formulations in its use as an oral delivery system for future experiments, we then  
immunized one group of mice by intragastric administration with the formulation OVA:NPL 
prepared in 5% NaHCO3 (a buffer used for intragastric administration of bacteria, etc.) to 
neutralize stomach acidity. At the same time, another group of mice was immunized with 
the formulation in the regular vehicle by intraduodenal injection, serving as a positive 
control for OVA:NPL induced-immune responses. Still, protection of NPL formulation with 
sodium bicarbonate was not efficient, as mice receiving this treatment in the stomach 
presented a lower response in all organs compared to mice that were immunized 
bypassing the stomach (Fig. 4.22A). Also in this case, statistical analysis was not 
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performed due to the reduced number of mice in each group, but the difference in OVA-
specific T cell proliferation was striking between mice immunized by intraduodenal 
injection and intragastric administration together with 5% NaHCO3. Regarding OVA-
specific Treg conversion, only a trend was observed with mice immunized by 
intraduodenal injection showing a higher percentage of Tregs (Fig. 4.22B). 
 
 
Figure 4.22. Effect of sodium bicarbonate in the protection of NPL from stomach acidity.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to immunization with OVA:NPL (200 µg OVA:1 mg NPL) by intraduodenal 
injection or intragastric administration buffered with 5% NaHCO3 after previous starvation during a 
long (19h) period. Five days later, the immune response in the OT II Ly5.2+ CD4+ T cell population 
of the indicated organs was analyzed by flow cytometry. (A) Percentage of proliferating OT II CD4+ 
T cells. (B) Percentage of Foxp3+ cells in OT II CD4+ T cells. Each data point represents an 
individual mouse. Data are shown as mean±SEM, n=3 mice/group.  
  
As sodium bicarbonate failed to protect NPL formulation in the stomach, we decided to 
test a more effective and lasting method to manipulate the stomach pH. Omeprazole is a 
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proton pump inhibitor that blocks the activity of H+/K+-ATPase in parietal cells, preventing 
the formation of an acidic pH in the stomach [184]. Since its effect is transient and varies 
between species, we measured the pH of the stomach content (under starvation, in order 
to mimic the conditions of mice undergoing immunization) before and after different time 
points of Omeprazole treatment (Fig. 4.23). Additionally, we also measured the pH in the 
duodenum of untreated mice (under the same starvation condition) to comprehend the pH 
level that one should aim for so as to efficiently protect NPL formulations. As expected, 
the transient effect of Omeprazole was observed and a gastric pH similar to that in the 
duodenum was obtained 4h after treatment. We decided to choose this post-Omeprazole 
treatment time point to immunize the mice intragastrically and not sooner, so both oral 
administrations were far apart and this procedure would not cause additional stress in the 
animals.  
 
 
Figure 4.23. Omeprazole treatment increases stomach pH.  
Starved C57BL/6 mice were treated with Omeprazole (40 mg/Kg body weight) in 0.2% NaHCO3 
and 0.5% methylcellulose by intragastric administration and the pH of the stomach content was 
measured after different time points. The pH of stomach and duodenum contents of not treated 
(NT) mice are also reported. Data are shown as mean±SEM, n=3-4 mice/group. One-way ANOVA 
followed by Bonferroni test was used to evaluate statistical significance. *p<0.05, **p<0.01, 
***p<0.001.  
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Figure 4.24. Effect of Omeprazole in the protection of NPL from stomach acidity.  
C57BL/6-Ly5.1 mice were adoptively transferred with naïve OT II Ly5.2+ CD4+ T cells and the next 
day were subjected to immunization with OVA:NPL (200 µg OVA:1 mg NPL) by intraduodenal 
injection or intragastric administration 4h after treatment with Omeprazole or vehicle alone after 
previous starvation during a long (19h) period. Five days later, the immune response in the OT II 
Ly5.2+ CD4+ T cell population of the indicated organs was analyzed by flow cytometry. (A) 
Percentage of proliferating OT II CD4+ T cells. (B) Percentage of Foxp3+ cells in OT II CD4+ T cells. 
Each data point represents an individual mouse. Data are shown as mean±SEM, n=3-5 
mice/group. One-way ANOVA followed by Bonferroni test was used to evaluate statistical 
significance. *p<0.05. 
 
In the same experimental setting that included adoptive transfer of OVA-specific CD4+ T 
cells, mice were then treated with Omeprazole or the vehicle alone and 4h later OVA:NPL 
was administered intragastrically. Pre-treatment with Omeprazole partially recovered the 
OVA-specific immune response found in mice immunized with the formulation directly in 
the duodenum, but its effect was not enough to induce a significantly higher response 
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than the one observed in mice treated with the vehicle alone and subjected to intragastric 
immunization (Fig. 4.24A). Again, the percentage of OVA-specific Foxp3+ T cells did not 
vary significantly between groups (Fig. 4.24B).  
Hence, although NPL exhibit some qualities that make them a good candidate for an oral 
delivery system, vulnerability to the stomach environment still needs to be addressed. 
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5 DISCUSSION 
 
Oral vaccination holds great promise for immunization in developing countries, elimination 
of bio-hazardous waste and pandemic preparation, nevertheless no oral influenza vaccine 
is commercially available so far. Designing a successful oral vaccine is not an easy task, 
as the antigen might get trapped in the mucus, digested or never cross the epithelial 
barrier and the administration dose is not necessarily the dose that reaches the mucosal 
tissue due to dilution in mucosal secretions. Moreover, a serious challenge, particularly 
when dealing with oral immunization, is the induction of tolerance against the delivered 
antigen [131]. 
 
5.1 CTA1-3M2e-DD as an oral vaccine 
We started our investigation by confirming the targeting ability of the universal influenza 
vaccine candidate, since our collaborators reported the binding of the adjuvant protein 
CTA1-DD (carrying the same targeting region) to B cells [113,181]. Thus, we replicated 
our collaborators’ in vitro experiment using CTA1-3M2e-DD, which showed that the 
targeting function of the DD region in this fusion protein was maintained, being able to 
bind to both mouse and human B cells, as observed before for CTA1-DD [113,181].  
Following the validation of CTA1-3M2e-DD targeting ability, we addressed our main 
question, whether this fusion protein is endowed with key features of an effective oral 
vaccine, i.e., to be able to cross the intestinal barrier and to be internalized by intestinal 
phagocytes in vivo. Although its functionality was preserved, CTA1-3M2e-DD showed a 
poor potential as an oral vaccine. The prolonged time that CTA1-3M2e-DD remained in 
the intestinal lumen overlying the epithelium, showed by imaging analysis of intestinal 
loops treated for 2h with the fusion protein, and the association mainly with CD45.2- cells, 
revealed by flow cytometry 4h after its intraduodenal administration, suggest that the 
fusion protein was trapped in the mucus layer. In fact, CTA1-3M2e-DD comprises the Ig-
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binding domain DD that was shown to bind to different Ig isotypes, including IgA [113], the 
predominant Ig in mucosal secretions and one of the molecules that is found in the mucus 
layer. One explanation for the retention of CTA1-3M2e-DD in the lumen is that it might 
bind to IgA present in the intestinal mucus layer, getting trapped for a long period and 
being prevented from crossing the epithelium. By attaching to the mucus layer, CTA1-
3M2e-DD has mucoadhesive properties, which are desirable for mucosal vaccines, but in 
this case further translocation across the epithelium did not occur. Not only was CTA1-
3M2e-DD excluded by the epithelial barrier, but also its uptake by the APC populations of 
interest in this setting was reduced. The fact that CTA1-3M2e-DD was almost exclusively 
taken up by a small percentage of CX3CR1high macrophages also supports the inability of 
this fusion protein to enter the lamina propria, as CX3CR1+ macrophages have the 
capacity to extend dendrites across the epithelium and capture luminal content [23,44,50].  
 
5.2 NPL as a delivery system for oral vaccines 
As CTA1-3M2e-DD was found to be unsuitable as an oral vaccine, we continued our 
studies on the nanoparticulate vaccine delivery system generated in our consortium to 
understand whether it could be of value to deliver antigens by the oral route. Contrarily to 
CTA1-3M2e-DD, confocal microscopy revealed that NPL quickly crossed the epithelial 
barrier, both in the mouse and human intestine. Moreover, NPL were found in CD103+ 
CD11b-, CD103+ CD11b+, CX3CR1high and CX3CR1int lamina propria APCs. Further 
investigation into the route of NPL entry in the intestine identified two different 
mechanisms by which NPL are taken up.  
 
5.2.1 Role of intestinal epithelial cells as a gateway for NPL  
On one hand, specific epithelial cells were found to contribute to the transport of high 
amounts of NPL. When staining NPL-treated intestinal tissue for markers of different 
epithelial cells, we observed that NPL-filled cells were MUC2+ Goblet cells. Antigen 
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sampling by Goblet cells is not a novelty. However, contrarily to what was once 
considered [80], not only small soluble antigens can pass through Goblet cell-associated 
passages. According to McDole et al., soluble antigens, such as dextrans, can fill Goblet 
cells, but there is a molecular weight exclusion limit for Goblet cell uptake, as 0.02 to 1 µm 
beads were excluded [92]. Nevertheless, NPL, which are approximately 76 nm in diameter 
[177], were taken up by Goblet cells. Moreover, Nikitas et al. reported that Listeria 
monocytogenes is able to cross the intestinal barrier by preferentially adhering to luminal 
accessible E-cadherin on Goblet cells, which in turn internalize the bacteria and release it 
in the lamina propria by exocytosis [183]. This suggests that rather than size, other 
characteristics are determinant for uptake by Goblet cells. Besides mechanisms 
depending on Goblet cell-specific targeting, it is possible that the chemical nature of the 
antigen plays an important role, since dextrans of different molecular weights (up to 2000 
kD) readily fill Goblet cells [92] and NPL, also composed of polysaccharides, behave 
similarly. 
The contribution of Goblet cells to NPL transport into the lamina propria might also explain 
the presence of NPL in the four lamina propria APC subsets and not in one in particular. 
NPL-containing Goblet cells probably release the vaccine vector indiscriminately in the 
lamina propria where NPL are then available to be phagocytosed by different APCs. 
However, the direct transfer of antigen from Goblet cells to specific APCs, such as 
CD103+ DCs, has been reported for low molecular weight antigens [92].  
Although NPL transfer from the lumen to the intestinal lamina propria was mainly 
associated with Goblet cells, we also found NPL uptake in Paneth cells, to a lesser extent. 
Additionally, one cannot exclude the involvement of paracellular pathways in NPL 
transportation, that indeed occur with dietary antigens in the intestine [185]. To address 
this point, an imaging technique offering higher resolution, as transmission electron 
microscopy, could be of interest. 
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5.2.2 Direct sampling of NPL by CX3CR1+ macrophages 
The second mechanism taking place in the uptake of NPL is the direct acquisition by 
CX3CR1+ cells. We have found that these cells in PP extend trans-epithelial dendrites 
across the FAE and sample NPL from the lumen. In the intestinal lamina propria, both 
CX3CR1int and CX3CR1high macrophages also contained NPL. However, direct sampling 
by these cells in the villi could not be confirmed, as trans-epithelial dendrites were not 
visualized by confocal microscopy and the presence of NPL+ CX3CR1+ cells may be the 
result of NPL uptake after Goblet cell-dependent transcytosis. It would be interesting to 
determine if NPL uptake by CX3CR1+ cells in the villi also occurs through trans-epithelial 
acquisition, at least partially, by comparing the percentage of NPL+ CX3CR1+ cells in the 
intestines of Cx3cr1GFP/+ and Cx3cr1GFP/GFP mice, as the homozygous strain, having both 
CX3CR1 alleles replaced by GFP, do not express the chemokine receptor and fail to 
extend protrusions [49].   
 
5.2.3 Delivery and presentation of antigen formulated with NPL 
Our results also show that, when formulated with NPL, OVA can be released in the lamina 
propria still conjugated with the vaccine vector, but also alone. Both forms of OVA were 
also visualized within intestinal epithelial cells. Dombu and colleagues studied the 
intracellular delivery of OVA in human airway epithelial cells by NPL [182]. Their results 
show that NPL are quickly taken up in this model and accumulate in clathrin vesicles and 
early endosomes. Here, they observed a gradual release of OVA from NPL and that these 
nanoparticles facilitate the escape of OVA from endosomes, which is apparently due to 
the charge of this protein at acidic pH. Their results may explain what we observed in the 
mouse intestine, as this mechanism of OVA release might also occur within the intestinal 
epithelial cells (previously identified as Goblet cells) that transport NPL into the lamina 
propria and subsequently release at least part of the antigen dissociated from the vaccine 
vector. 
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Another important aspect to consider when developing a new mucosal vaccine, is to 
trigger protection upon vaccination with low doses of antigen. To understand whether NPL 
are advantageous as a vaccine vector in the induction of an immune response, we 
compared OVA-specific responses in lymphoid organs when the antigen was delivered 
alone or loaded in NPL. We observed an increased proliferation of adoptively transferred 
OVA-specific CD4+ T cells in mLN and spleen upon OVA:NPL immunization, which is 
encouraging for the use of NPL as vaccine carriers. This increase was not found in PP, 
though, meaning that antigen presentation in this tissue occurred similarly when the 
antigen was free or formulated. This could reflect that, at this level, the amount of antigen 
that is taken up is not enhanced by NPL delivery or even a different mechanism of 
epithelial/trans-epithelial transportation takes place. Noteworthy, high proliferation of 
antigen-specific CD4+ T cells in mLN and PP was expected, but the finding that 
comparable proliferation occurred in spleens was surprising. This strong response in the 
spleen can be the result of recirculation of T lymphocytes that egress from lymphoid 
organs close to the site of induction, where antigen recognition and T cell activation 
occurs. Another hypothesis is that, as we observed by imaging analysis revealing the 
localization of NPL throughout the lamina propria, the vaccine vector might be able to 
cross the intestinal endothelium and end up in the bloodstream, where it can then spread 
systemically and reach the spleen. This needs to be further investigated, for instance by 
measuring the fluorescence intensity in the serum of mice injected with fluorescently-
labeled NPL in the intestine or by in vivo imaging, tracking the NPL fluorescence over time 
and following their eventual accumulation in distant organs. 
Also encouraging was the fact that, despite the increase of OVA delivery and presentation 
when formulated with NPL, this was not translated in induction of OVA-specific Tregs in 
any of the analyzed organs, as tolerance induction is a major concern when dealing with 
oral vaccines. Interestingly, McDole and colleagues found that antigens transported 
through Goblet cell-associated passages are directly delivered to CD103+ DCs in the 
lamina propria, a subset closely linked to the establishment of oral tolerance [92]. 
Additionally, it was reported that mucus taken up by APCs can act as a modulatory signal, 
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imprinting a tolerogenic phenotype on these cells and leading to enhanced oral tolerance 
[10]. Nevertheless, this was not verified in our study, even though CD103+ DCs were able 
to take up NPL. One can speculate that this is due to the fact that the antigen loaded in 
NPL was not presented by this subset of APCs in the GALT. Another possibility is the 
absence of mucus uptake when NPL are internalized, preventing the assimilation of this 
tolerogenic signal. The Th1 and Th2 responses were also evaluated and we found that 
OVA:NPL induces a higher percentage of OVA-specific IFNγ-producing CD4+ T cells in 
PP, but not in mLN and spleen. Whether this is due to antigen presentation and CD4+ T 
cell priming by different subsets of APCs, which in turn imprint on these cells different 
phenotypes, is still an open question. 
 
5.2.4 Starvation as a potential modulator of adaptive immune responses 
after oral immunization  
The circadian clock is perceived by molecular machineries and allows regulation of 
different physiological processes according to variations in the environment [186]. We 
realized, from preliminary results on the advantage of NPL formulation, that mice in the 
same treatment group (OVA:NPL) presented variable responses and we hypothesized 
that the different immunization timing across the group could be the cause of such 
variability. Indeed, recently it was shown that lymphocyte trafficking in lymph and lymph 
nodes fluctuates throughout the day and this process is dependent on circadian clocks 
that trigger lymphocyte homing and egress [187]. Consequently, immunizations occurring 
at different time of the day shape different adaptive immune responses. We therefore 
investigated the impact of OVA:NPL immunization at distinct times, but our results showed 
that comparable immune responses were obtained and the circadian rhythm was not 
playing a role in this matter.  
Our alternative hypothesis was the contribution of starvation. In fact, it was shown that 
also the intestinal microbiota can undergo diurnal oscillations, leading to different 
compositional and functional microbiota profiles throughout the day that are influenced by 
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feeding patterns [188]. Different periods of starvation can consequently shape the 
microbiota profile, which in turn may alter the intestinal homeostasis and its immune 
component. We evaluated the individual role of starvation in OVA-induced CD4+ T cell 
proliferation after OVA:NPL immunization, as well as in combination with immunization 
occurring at different time of the day, and confirmed that mice undergoing a longer period 
of starvation (even only 3 more hours) presented a better response, independently of 
immunization time. Whether this effect relies on the fasting itself (as lack of food could 
trigger a compensatory mechanism that enhances nutrient absorption and this is reflected 
by an increase in the uptake of NPL formulation) or on microbiota-related alterations (that 
shape the immune response according to their numbers and composition under 
starvation), remains to be clarified.  
 
5.2.5 Instability of NPL formulations in the stomach  
Finally, we addressed the capacity of NPL to protect the loaded antigen from stomach 
degradation by immunizing mice with OVA:NPL through intragastric administration and 
comparing their OVA-specific response with mice in which immunization bypasses the 
stomach. We concluded that the effect of NPL as a vaccine vector was compromised 
when it was administered in the stomach, showed by lower responses to OVA. According 
to Dombu et al., acidic conditions, as found in the stomach, favor interaction of NPL-
loaded OVA with proteases, by diminishing OVA attraction to the cationic nanoparticle and 
inducing its release, and consequently increasing its exposure to degradation [182]. 
Although NPL might survive through the GI tract, its oral delivery might compromise an 
immune response, as the antigen is no longer associated to the vaccine carrier. 
Neutralization of stomach acidity with sodium bicarbonate, which is a commonly used 
buffer for oral administrations, did not enhance vaccine effectiveness. Nevertheless, we 
confirmed the role of the stomach pH in the modification of OVA:NPL formulation by 
increasing the stomach pH to levels found at steady-state in the duodenum. However, 
manipulation of stomach pH with a proton pump inhibitor was only transient, which might 
have lead only to a partial amelioration of OVA:NPL stability, as the transit time from the 
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stomach to the small intestine might be longer than the effect of the drug. Protection from 
the stomach acidity is an important issue to take into consideration when developing an 
oral vaccine delivery system. Nevertheless, for the use in humans, this problem can be 
easily solved by loading NPL formulations in pH-resistant capsules, whereas for studies in 
animals, particularly mice, the dimensions of commercially available capsules are not 
adequate for them.   
 
In conclusion, we have shown that, while the influenza vaccine candidate CTA1-3M2e-DD 
is retained in the intestinal lumen for a long period, NPL as vaccine vectors are indeed 
able to deliver the loaded antigen, to cross the intestinal barrier with Goblet cells as an 
important gateway and to be taken up by different intestinal APCs, with no apparent 
induction of tolerance and a Th1 response to the delivered antigen in PP. Moreover, the 
effect of starvation on the immune response in this setting was recognized. Further 
experiments are underway to characterize the ability of NPL to induce DCs activation after 
phagocytosis and the modulation of cytokine production, as well as to determine their 
potential to induce in vivo antigen-specific IgA and IgG following sequential immunizations 
in the intestine.        
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